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Throughout nature, many proteins provide a specific function in response to 
some input signal (e.g., phosyphorylation, pH, etc.), a process that is oftentimes 
described as switching a protein “on” or “off.”   The advent of protein engineering has 
allowed for the creation and understanding of chimeric proteins for uses in a number of 
applications such as therapeutics, biosensors and energy production.  Two proteins, 
hemagglutinin (HA) of fowl plague influenza virus and a chimeric protein comprising a 
fusion between the LFA-1 I domain and the EF3 and EF4 hands of calmodulin, have 
been investigated in this dissertation.  Both of these proteins undergo structural 
rearrangements in response to an input signal in a process that could be described as 
molecular switching.  
 Hemagglutinin (HA) is a viral fusion protein that undergoes an irreversible 
conformational change upon acidification to catalyze the fusion of endosomal and viral 
membranes.  Directed evolution was previously used to identify novel mutants with 
activation pH across a range of 4.8 – 6.0; wild-type HA activates around pH 5.2.  
Examination of library mutants has enabled us to identify individual amino acids 
responsible for phenotypic changes and thus provides additional structure-function 
insight highlighting the importance of HA1 headgroups in pH sensing.   
Secondly, we have improved a previously created chimeric protein switch using 
the integrin LFA-1 I domain and the EF3 and EF4 hands of calmodulin; the original 
switch protein had a 2.4-fold increase for the I domain ligand, ICAM-1, in the presence 
of a calmodulin target peptide. Directed evolution has revealed a mutant switch with an 
additional twenty-fold increase in ICAM-1 binding in the presence of peptide.  
Additionally, the specificity of the chimeric protein for the original peptide sequence has 
been engineered, creating a new switch that responds to a different peptide sequence 
rendering the original peptide nonfunctional.  Both proteins, hemagglutinin and the I 
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domain-calmodulin fusion, represent the importance of conformational changes in 
controlling protein function.  The ability to manipulate these changes underscores the 
power of protein engineering and directed evolution and can lead to the development of 
complex biomolecules that can be used in a variety of applications. 
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Chapter 1 :  Introduction 
1.1   Background 
 Nature is beautifully complex with a multitude of processes, proteins, and 
interactions to inspire new ideas for the creation of technologies to fight diseases and to 
better understand the mechanisms behind them.  Characterizing, understanding, and 
engineering different proteins can lead to the development of smarter materials to be 
used for different applications such as targeted drug delivery, biosensing, and molecular 
imaging.    
 The unique sequence of amino acids that defines a specific protein heavily 
influences the three-dimensional structure, or shape, of the protein.    Myoglobin, an 
iron- and oxygen-binding protein found in many animal cells, was the first protein to 
have its three-dimensional structure solved in 1958.1  Since 1958, the number of protein 
structures that have been determined has grown exponentially such that the Protein 
Data Bank now contains close to 88,000 protein structures (www.rcsb.org).  It is this 
three-dimensional structure that is key in determining the function of a protein.  
Antibodies have a distinct Y-shape, consisting of two variable regions and an Fc 
domain, which is critical to the immunological function of the protein.  Variable domains, 
which contain the antigen binding site, have extreme sequence diversity allowing 
antibodies to bind foreign antigens with great specificity.  Conversely, the Fc domain is 
composed of highly conserved sequences  and has receptor binding cites for 
engagement with cells of the immune system.2  Other proteins, such as hemoglobin can 
have flexible structures that provide the basis for their function.3; 4 As one oxygen 
molecule binds to a heme in one of the hemoglobin subunits, strains in the protein 
caused by the location of the hemes are relaxed allowing the protein to change its 
shape to allow for better positioning of the hemes and thus allowing oxygen to bind with 
higher affinity.5   It is the intrinsic ability of proteins like hemoglobin to change, or switch, 
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their shape that led to the understanding of allostery and serves as a fundamental 
principle in this dissertation.  
1.1.1  Allostery 
Protein structure and conformational flexibility play a critical role in controlling 
protein function.  A number of different types of proteins exploit structural 
rearrangements to carry out their respective functions such as enzymes, chaperonins, 
membrane fusion proteins and intergrins.6; 7; 8; 9  The conformational changes of a 
protein often occur in response to effector molecules (metabolites, ATP, DNA, RNA, 
peptides, etc.) that bind at sites distinct from the active site resulting in a reversible 
conformational change in the three dimensional structure of the protein, a mechanism 
known as allostery.10  In the seminal paper first describing protein allostery, Monod and 
colleagues describe a number of enzymes that are allosterically regulated, such as 
ATCase and threonine-deaminase.10  GroEL, a molecular chaperone that assists in the 
folding of nonnative polypeptides, performs an intricate array of allosteric movements 
choreographed by cooperative ATP binding. 7  Integrins, which will be discussed in 
more detail below, also undergo drastic conformational refolding in response to 
intracellular signals in order to adopt a high affinity conformation and assist in leukocyte 
firm adhesion.9; 11 The integrin, lymphocyte function-associated antigen-1 (LFA-1, 
integrin αLβ2) is able to firmly adhere to sites of inflammation by high affinity binding 
through its inserted (I) domain.  The affinity of αL I domain for its ligand, ICAM-1, is 
allosterically regulated in response to the reversible „pulling‟ of its α7 helix which causes 
a series of rearrangements within the domain resulting in a high affinity state. 
 However, not all conformational rearrangements are reversible.  For instance, 
viral fusion proteins, such as HIV-1 GP120/41 and hemagglutinin (HA), expressed on 
the surface of enveloped viruses mediate the merging of two biological membranes  and 
undergo irreversible conformational changes in response to ligand binding or lowered 
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pH, respectively.12  The viral fusion protein, gp120/41, is expressed on the surface of 
HIV-1 and effects entry of the virus into the cell.  It is structurally similar to influenza 
hemagglutinin, which will be discussed in detail below, as both proteins are processed 
as fusion incompetent polypeptides (HIV-1 GP160 and influenza HA0) and are 
subsequently proteolytically cleaved into a fusion competent molecule.  Upon exposure 
to an activating stimulus (CD4 binding for gp120/41 and low pH for HA) the fusion 
proteins undergo an irreversible conformational switch to an extended, stable coiled coil 
conformation exposing their fusion proteins (N-termini of gp41 and HA2, respectively) to 
the target membrane.12; 13   Insertion of the fusion peptides followed by refolding of the 
fusion proteins brings the two membranes in close proximity to each other allowing 
them to merge. 
 Allosteric rearrangements and large-scale conformational refolding can be 
thought of as a protein switching mechanism.  In other words, due to an external input a 
protein can be forced to switch conformations.  This dissertation will explore this 
concept of protein switching by characterizing the viral fusion protein, hemagglutinin, 
and exploiting the concept of allostery, using the I domain of the LFA-1 integrin and the 
EF3 and EF4 hands of calmodulin to engineer a chimeric fusion protein switch.  In the 
case of αL I domain, conformational switching will be shown to be induced by the 
binding of an exogenous peptide and hemagglutinin mutations will be identified that 
point to a hotspot within the protein structure that likely controls its switching 
mechanism.   
1.1.2  Protein switches 
Different design motifs have been used to engineer a number of different protein 
switches.  Common design motifs for engineering protein switches include protein 
splitting, domain insertion, mutually exclusive folding and domain swapping.14; 15  Most 
switches rely on using enzymes or reporter proteins, such as luciferase, GFP, β- 
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lactamase, or dihydrofolate reductase (DHFR) as the output domain to provide an easily 
readable signal upon activation by the input domain.14; 15  An early example of an 
engineered switch involved domain insertion of calmodulin into a circularly permuted 
GFP.  Upon the addition of calcium, the GFP-calmodulin switch demonstrated about an 
8-fold enhancement in fluorescence.16  β-lactamase (BLA) has been routinely used in 
protein switch construction as hydrolysis of beta-lactam antibiotics makes screening 
mutants very efficient.  Domain insertions with BLA to control substrate hydrolysis 
include the maltose binding protein (MBP), calmodulin (CaM), and a short hexapeptide 
to engineer a metal ion binding site.17; 18; 19 Mutually exclusive folding is another design 
motif in engineering protein switches where the folding of one protein causes the 
unfolding of its fusion partner.  A fusion where human ubiquitin is inserted into an 
exposed loop of B. amyloliquefaciens barnase showed that by controlling barnase 
folding via ubiquitin, cell viability could be regulated.20   Regardless of the design 
method chosen, controlling protein function by an input domain provides an additional 
level of regulation. 
1.1.3  Possible applications of engineered switches 
A large number of devastating illnesses are either virally induced (e.g. HIV/AIDS, 
T-cell leukemia)21 or are associated with chronic inflammation (e.g. rheumatoid arthritis, 
Crohn‟s disease, psoriasis)22.  Both proteins that will be studied in this thesis are either 
heavily involved in inflammatory responses - I domain - or from the same family of 
proteins responsible for seasonal flues - hemagglutinin - that also share many structural 
and functional properties with retroviral proteins such as the HIV fusion protein 
gp120/41.  Therefore, these proteins serve as convenient starting points for the 
development of target specific molecules. 
Site-specific imaging or drug delivery is a complicated problem with a number of 
factors such as particle size, circulation half-life, immunogenicity, and target specificity 
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that need to be considered.23; 24  Recently, the αL I domain has been conjugated to the 
surface of nanoparticles for targeted delivery of drug and gene therapies to cells over 
expressing ICAM-1 both in vitro and in vivo.25; 26; 27  These molecules use previously 
engineered high affinity I domain28 to selectively target ICAM-1 making these 
nanoparticles highly efficient at targeting tumors where drug delivery by the permeability 
and retention (EPR) effect is less efficient.  Designing a protein switch where I domain 
affinity is regulated by the presence of exogenous peptide would provide an additional 
layer of specificity in targeted imaging and delivery systems.  Further engineering of 
peptide specificity would enhance the targeting capabilities.     
Characterization and understanding of hemagglutinin and what leads to its 
conformational switching could lend insight into similar proteins‟ (e.g., HIV-1 gp120/41) 
modes of action therefore leading to more effective retroviral drugs.  The fusion peptide 
of HA2 has also been shown to be effective in promoting fusion between a liposome 
and cellular membranes as an efficient means of delivering genetic material to a cell.29; 
30 A better understanding of HA allows for possible engineering of ligand binding sites 
into locations of the hemagglutinin that are critical in pH sensing.  Grafting in a ligand 
binding site in a pH sensing „hot spot‟ could allow for controlled release of drugs 
encapsulated in liposomes by the presence or absence of a ligand, providing more 
control over current approaches where only the fusion peptide of hemagglutinin is used 
to assist in liposome-membrane fusion.   One concern about an approach of this nature 
would be immune responses due to the presence of a viral protein. 
  Development of a protein switch, along with the ability to alter ligand specificity, 
would demonstrate the profound ability to build a biomolecule that could do almost 
anything; possibilities include selectively delivering a drug to a specific target or 
developing a biosensor for security or safety purposes.  An engineered protein switch 
could be used to benefit society in a nearly unlimited number of ways.   
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Chapter 2 :  Characterization of hemagglutinin mutants for 
identification of novel pH sensing mutations 
 
2.1  Introduction 
 Membrane fusion is a highly evolved process that accounts for many biological 
activities including cell-cell fusion (e.g. sperm and oocyte), extra- and intra-cellular 
fusion of pathogens with host cells (enveloped viruses), or intracellular fusion of 
organelles.8  The process by which the influenza viral membrane fuses with a cellular 
endosomal membrane, via the viral fusion protein hemagglutinin (HA), to release its 
viral RNA within the host cell is a highly studied, model fusion event.8; 12; 31; 32  Following 
receptor binding, internalization of the virus by endocytosis leaves the viral genome 
separated from the cell cytoplasm by two membranes, endosomal and viral.  Fusion of 
these two membranes is energetically unfavorable without the additional energy 
released by HA upon its irreversible, conformational change in response to the lowered 
pH of the acidified endosome.33; 34   
2.1.1  Hemagglutinin 
 The typical membrane fusion pathway involves four intermediate states that 
include 1) the close contact of the opposing membranes, 2) destabilization of the 
membranes,  3) a hemifusion state and 4) finally the complete fusion pore 8; 33.  Many 
mechanisms of action can lead to membrane fusion but a well characterized pathway 
involves fusion proteins, such as hemagglutinin (HA) (Figure 2. 1).  A better 
understanding of membrane fusion, and in particular, the action of hemagglutinin can 
lead to the design of better smart molecules for such practices as targeted drug or gene 








Figure 2. 1  Proposed role of HA in membrane fusion.  HA1 is not shown for clarity.  At 
acidic pH, HA refolds to expose its fusion peptide to the target membrane (1).  Trimers 
aggregate quickly, followed by a second refolding step at the C-terminal end of HA2 
where the kink region (purple) undergoes a helix-to-loop transition (3 and 4).  The 
refolding of the C-terminal end brings the two apposing membranes into close proximity 
allowing for the formation of a transitive hemifusion state (5).  The transmembrane 
domains and fusion peptides of HA are brought together allowing for pore formation (6). 
Figure 2.1 from Gruenke, J.A., Armstrong, R.T., Newcomb, W.W., et. al.:  New Insights 
into the Spring-Loaded Conformational Change Influenza Virus Hemagglutinin.  J. Virol. 









Hemagglutinin is a membrane glycoprotein composed of three identical 
heterodimer subunits, HA1 and HA2 (Figure 2.2 A). The HA1 subunit is approximately 
330 amino acids in length and extends 96 Å from its amino-terminal end near the viral 
membrane distally into a globular head  domain composed of an 8-stranded β-sheet 
structure, which contains the binding pocket for sialic acid.36  The carboxy-terminal 
region of the polypeptide extends 60Å back toward the viral membrane anti-parallel to 
the amino-terminal region of HA1.36  The HA2 subunit is approximately 220 amino acids 
composed of a short alpha helix (29Å) connected by an extended chain to a long α-helix 
(76Å) followed by a transmembrane domain and short cytoplasmic tail.36; 37  The 
extended loop of HA2 connecting the two helices, referred to as the B-loop, undergoes 
a loop-to-helix transition to extend the coiled-coil structure of the protein which relocates 
the fusion peptide more than 100 Å from its buried position in the neutral pH 
conformation towards the target membrane(Figure 2.2 A).12; 38; 39  Each subunit is 
synthesized as a single polypeptide chain (HA0) and trimerizes in the endoplasmic 
reticulum.40  The trimers are immediately transported to the Golgi complex where the 
HA0 subunits are cleaved by either a subtilisin-like (polyarginine H5 and H7 subtypes) 
or trypsin-like (all other subtypes are monoarginine) protease either in the trans-Golgi or 
in the plasma membrane region39; 41.  Cleavage of HA0 into the disulfide-linked 
HA1/HA2 subunits results in the newly formed N-terminal residues of HA2, known as 
the fusion peptide, burying into a cavity of ionizable residues of the trimeric coiled-coil 
(Figure 2.2 B).32; 42  The ectodomain of HA is stabilized by a number of intramolecular 
interactions consisting of intra-domain and -subunit disulfide bonds, polar and 
hydrophobic interactions between adjacent α-helices,36 and a number of single and 
complex salt bridges.43 
Hemagglutinin binds to sialyted cell-surface receptors where the enveloped virus 
is endocytosed.  The lowered pH of the endosome causes an irreversible 
conformational change in the hemagglutinin structure leading to fusion of the viral and 
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Figure 2.2   Influenza hemagglutinin.  A) Trimer of hemagglutinin monomers showing 
three major structures on the pathway towards low pH refolding where the HA1 subunit 
is shaded blue, HA2 is red and the N-terminal HA2 fusion peptide is yellow.  Left panel 
and (B), HA is synthesized as a single polypeptide chain HA0 before proteolytic 
cleavage resulting in a disulfide-linked HA1/HA2.  Middle panel, following cleavage of 
HA0 the newly formed fusion peptide imbeds itself into the trimeric coiled-coil.  Right 
panel, under acidic conditions the protein undergoes an irreversible conformational 
change that results in the dissociation of HA1 headgroups (not shown) and relocates 
the fusion peptide more 100 Å towards the target membrane.  B)  Left and middle 
panels, rearrangement of the fusion peptide.  The black sphere represents the N-
terminal glycine of the newly formed HA2 subunit.  Right panel, the kink angle of the 
fusion peptide which is essential for insertion into the target membrane as it allows the 
more hydrophobic N-terminal half of the peptide to associate with the hydrophobic 
bilayer while the C-terminal half is more exposed to a hydrophilic environment. Figure 
2.2 A and B reprinted from Cross, K.J., Langley, W.A., Russell, R.J., Skehel, J.J., and 
D.A. Steinhauer.  Compositions and Functions of the Influenza Fusion Peptide. Protein 












endosomal membranes.  Protonation of charged residues in both the HA1 head group45 
and fusion peptide pocket46; 47 are disrupted resulting in the HA1 head groups 
dissociating and allowing the fusion peptide to be exposed to the target membrane.  
The fusion peptide is composed of two short helices, the N-terminal helix consisting of 
conserved hydrophobic and glycine residues and the C-terminal half that is amphipathic 
with a number of charged and polar residues, that adopts a kink angle in the center of 
the helix of approximately 105° (Figure 2.2 B).48; 31; 49; 50  The mechanism of membrane 
fusion mediated by the viral fusion peptide remains unclear (i.e., whether the fusion 
peptide inserts into the endosomal membrane or the viral membrane, reviewed in ref. 8).  
Most current structural data suggest that the fusion peptide is extruded from its 
hydrophobic cavity in the coiled coil structure and extended towards the target 
membrane (e.g., the endosomal membrane) where it inserts.  Rearrangements occur at 
the membrane proximal end of HA2 causing the C-terminal part of the helix to break 
and fold back upon itself bringing the fusion peptide and transmembrane domains into 
close proximity, and thus the apposed membranes44; 46; 51. The membrane defects 
imposed by the fusion peptide and the negative curvature of the membrane during the 
refolding of HA are predicted to lower the energetic barrier to allow fusion to proceed 
(Figure 2. 1).  
While the precise mechanism of hemagglutinin-mediated membrane fusion is not 
explicitly understood, there is agreement in the literature as to some necessary steps on 
the pathway toward membrane fusion.  First, at least eight HA trimers rapidly aggregate 
at the site of fusion in a non-rate limiting step, of which only two or three are needed to 
refold to promote fusion.52; 53  White and colleagues demonstrated that viral membrane 
fusion is a cooperative process that involves the concerted action of at least three 
timers, which has also been verified through single-particle kinetic experiments.54; 55  
This cooperativity is likely responsible for an autocatalytic activation phenomenon 
employed by HA.  It is well understood that hemagglutinin aggregates at the site of 
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membrane fusion and that this clustering often occurs in “lipid raft” microdomains.56  
These clusters of HA coincide neatly with the idea of synchronized activation proposed 
by Markovic and colleagues.  The authors suggest that adjacent HA proteins at high 
local densities will undergo a synchronized conformational change to effectively lower 
the energy barrier separating the metastable conformation from the final low-energy 
conformation, ensuring that the virus will efficiently carry out the membrane fusion 
process.57  Likewise, Lee, Goulian and Boder also described a cell-scale autocatalysis 
mechanism where only two states, activated or inactivated HA, exist.  Data show that 
freshly expressed protein can be activated by the presence of previously refolded HA 
implying a feedback autocatalysis mechanism.58  
2.1.2  Spring-loaded model of HA 
The structural transitions that lead to the final irreversible HA conformation have 
been well characterized with crystal structures depicting each of the important 
intermediate structures.  As mentioned earlier, HA is processed as a single polypeptide, 
HA0, which is thermodynamically stable and unable to undergo the irreversible 
conformational change at low pH.  Proteolytic cleavage of HA0 results in disulfide-linked 
HA1 and HA2 subunits and the repositioning of the 20 N-terminal amino acids of HA2, 
the fusion peptide, into a hydrophobic cavity within the HA trimer.  This structure is 
considered to be trapped in a metastable state at neutral pH and readily refolds to a 
lower energy conformation at low pH or at neutral pH with the addition of a denaturant.59 
The lowest energy conformation of HA occurs at the pH of fusion where the B-loop has 
undergone a loop-to-helix transition resulting in a HA trimer that is stabilized by an 
extended coiled coil structure.  The transition from the metastable neutral pH structure 
to the stable low pH structure is supported by the spring-loaded model for HA 
refolding.38; 59 
The spring-loaded model for hemagglutinin refolding is as follows:   
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 Proteolytic cleavage of HA0 results in a metastable structure of HA that is 
primed for refolding 
 HA1 headgroups act as clamps preventing the B-loop of HA2 to undergo 
its loop-to-helix transition 
 Dissociation of HA1 headgroups likely precedes the loop-to-helix transition 
 The loop-to-helix transition results in the formation of an extended coiled 
coil structure, a lower energy conformation 
Before the low pH structure of HA was solved, the residues composing the B-
loop of HA2 were shown to adopt a helical structure at low pH in solution.38  This 
indicated that the B-loop of HA2 prefers a helical conformation but is blocked from 
refolding by the HA1 headgroups.  Studies have expanded upon the importance of the 
B-loop transition by introducing mutations to stabilize this loop and prevent HA refolding 
into an extended coiled coil structure.  Mutation of H2 HA2 R106H stabilizes the trimer 
well below the pH of fusion for wild-type H2 HA.60  Crystal structures of this mutant at 
neutral and low pH indicate that side chain interactions between the loop and the long α 
helix of HA2 are lessened at low pH, evidence of a possible early intermediate in the 
spring-loaded mechanism.60  A double proline HA mutant, F63P/F70P (H3 HA2 
numbering), resulted in a fusion incompetent protein whose coiled coil structure was 
interrupted by the proline substitutions following irreversible low pH refolding.35  It was 
argued that while the double mutant refolded at low pH, the proline mutations effectively 
shortened the coiled coil structure preventing the necessary tension needed for 
membrane fusion to occur indicating that the loop-to-helix transition is a necessary 
component of the spring-loaded model.35  Intersubunit disulfides engineered to prevent 
the HA1 headgroups from dissociating at low pH abolished HA refolding and membrane 
fusion indicating the likely necessity of HA1 headgroup dissociation in HA refolding.61; 62   
Finally, targeted molecular dynamics using neutral and low pH crystal structures (1HGF 
14 
 
and 1HTM, respectively) indicated that the spring-loaded conformational mechanism is 
the most energetically favorable pathway between the structures.63 
A number of studies have examined mutations throughout the structure of HA to 
identify pH sensing mutations and their effect on HA refolding.64; 65  These studies 
genereally relied upon sequence analysis and/or structural information to identify 
residues or parts of the structure to target for identification of pH sensing residues.  
Previous work in our lab developed a flow cytometry assay that decouples HA refolding 
from membrane fusion.58 This assay was then used in a directed evolution experiment 
to generate HA mutants whose structures are either stabilized or destabilized with 
respected to wild-type H7 HA. We have analyzed the different mutations that came from 
this previous directed evolution work in order to try and identify individual mutations that 
are responsible for pH sensing and to gain further insight into the structure-function 
relationship of HA.  Analysis of individual mutations mapped the majority of the changes 
to the HA1 domain, and more specifically to the interface of two HA1 subunits.  While 
there is agreement in the literature that some loosening of the HA1 domains precedes 
the large structural rearrangements leading to the fusion competent structure of HA, our 
data suggest that HA1 plays a more significant role in controlling HA refolding.   
2.2  Materials and Methods 
2.2.1  DNA, library and point-mutant construction 
  Kozak sequence GCCACC was added to the wild-type FPV HA gene51 (from 
A/FPV/Rostock/34) by PCR in order to increase the expression in mammalian cells. 
Amino acid residues HA2 11-20 (i.e. fusion peptide residues 11–20) were replaced with 
the c-myc epitope tag sequence via PCR, and referred to as HA3.1, as previously 
described.58   HA3.1 DNA was randomly mutated by non-biased error-prone PCR using 
Mutazyme II polymerase (Stratagene, Santa Clara, CA). PCR products were purified by 
electroelution and digested with Xho I and Not I. They were then ligated into pLNCX2 
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retroviral expression vector (Clontech, Mountain View, CA). E.coli transformation was 
done by electroporation and the cells were cultured in 250 ml LB Amp medium in a 37 
°C shaker for 36 hours. The library size was determined by plating 20 ul of the culture 
after 36 hours of incubation and counting the number of colonies on the plate after a 20 
hour incubation at 37 °C. The number of colonies was then multiplied by 20,000. Point 
mutants were created by site-directed mutagenesis using the QuikChange II XL kit 
(Stratagene) following the manufacturer‟s protocol.  Primers were created with a 
minimum of 15 nucleotides of homology on either side of the desired amino acid 
change.   Point mutants were confirmed by sequencing prior to retroviral transduction of 
the point mutant to create a stably-expressing HA with the mutation. 
2.2.2  Cell culture 
   All mammalian cell cultures were maintained at 37°C and 5% CO2.   NIH-3T3 
cells (a gift from Dr. John Crocker, University of Pennsylvania), EcoPack2-293 and 
AmphoPack-293 (Clontech, Mountain View, CA) were grown in Dulbecco‟s Modified 
Eagles Medium (DMEM) (Hyclone, Logan, UT) supplemented with 10% (v/v) fetal 
bovine serum (Hyclone), 100 U/ml penicillin and 100 ug/ml streptomycin (Life 
Technologies, Grand Island, NY).  EcoPack2-293 and AmphoPack-293 are HEK293 
derived cell lines stably expressing viral structural genes gag, pol and env for safe 
production of infectious, replication-incompetent virions.  Media was replaced roughly 
every 48 hours and cultures were passaged prior to reaching confluency (~4 days).  
During passaging, cells were washed with Dulbecco‟s phosphate buffered saline 
(DPBS) containing 8 g/L NaCl, 200 mg/L KCl, 1150 mg/L Na2HPO4, 200 mg/L KH2PO4.  
The cell monolayers were then detached using either 0.25% trypsin-EDTA (routine 
passage) or 0.05% trypsin-EDTA (for analysis). 




2.2.3  Retroviral expression and viral titer determination 
1×106 EcoPack 2-293 (BD Biosciences, Mountain View, CA) packaging cells 
were plated in each well in a 6-well plate 16-20 hours before transfection, and 
transfected with 10 μg of retroviral expression vector library. Virus containing medium 
was collected at either 24 hours or 48 hours post-transfection and filtered through a 
0.45 μm cellulose acetate filter. NIH-3T3 cells were plated 24 hours prior to infection in 
6-well plates at a density of 1×105 cells per well. In order to determine the viral titer, six 
10-fold serial dilutions of the virus containing medium was prepared, and NIH-3T3 cells 
were infected by adding 1 mL of the diluted medium to the wells with the final polybrene 
concentration of 4 μg/ml. The medium was replaced with selective medium containing 
100 μg/ml of G418 (Life Technologies) 24 hours post-infection. The viral titer was 
estimated by counting the number of colonies in the highest dilution that contained 
colonies after one week of selection and by multiplying the number of colonies by the 
dilution factor. For flow cytometry analysis of HA3.1 library expression in NIH-3T3 cells, 
cells were stained with HC2 mouse mAb and anti-mouse-phycoerythrin (PE) 24 or 48 
hours post-infection..  
2.2.4  Stable selection of HA library expressing cells 
Cells were infected and selected by the method used for viral titer determination. 
Non-infected cells were used as a negative control and the cells were cultured in the 
selective medium until there were no viable cells observed in the control population. 
Expression levels before selection and after selection were analyzed by flow cytometry 
after HC2 mouse mAb and anti-mouse-PE staining.  
2.2.5  Analysis of pH-induced activation: 
  Adherent, non-confluent HA3.1 or wt HA and single point mutant expressing 
HEK293 cells were detached using 0.05% trypsin-EDTA and cell suspension aliquots 
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were transferred to 1.5mL microcentrifuge tubes and placed on ice.  The HA expressing 
cells were washed twice with PBS+0.1%BSA  (8 g/L NaCl, 200 mg/L KCl, 1440 mg/L 
Na2HPO4, 240 mg/L KH2PO4, and 1 g/L BSA) at 500xg using a benchtop 
microcentrifuge. The cells were then pH-pulsed for 5 minutes at room temperature at 
the appropriate pH. After the pH pulse HA3.1 were double-stained with mouse 
monoclonal anti-FPV HA1 (HC2) and chicken anti-c-myc mAb. Wild-type HA or single 
mutant HA expressing cells were labeled with either anti-FPV HA1 (HC2) or the trimer 
and conformation specific mAb, HC58.66  Primary antibody incubations were done at 
1:100 dilution on ice for 30-60 minutes.  Following the primary incubation, the cells were 
washed again with PBS+0.1% BSA and then labeled with a fluorescent secondary 
antibody at a 1:100 dilution and incubated on ice 30-60min.  Following the secondary 
incubation, the cells were washed again in PBS and then analyzed by flow cytometry.  
Only viable cells, as determined by propidium iodide (BD Biosciences) exclusion (10 
μL/106 cells for 15 minutes at room temperature) and/or light scattering, were included 
in the analysis by flow cytometry, and at least 10,000 gated events were analyzed for all 
flow cytometric experiments.  
2.2.6  Determination of Transition pH  
Viable cell populations were determined by light scattering and gated for 
analysis. The median fluorescence intensity (MFI) of the gated population was 
determined using FlowJo flow cytometry analysis software (Ashland, OR).  Plots of MFI 
versus pH were created using the statistical software package Prism (Graphpad, La 











Where Y is the median fluorescence at a given pH, X is the pH, „Bottom‟ is the lower 
plateau of the dose response curve, „Top‟ is the upper plateau of the curve and EC50 is 
the pH at which HA is assumed to have transitioned to an irreversible conformation.  An 
EC50 value was extracted from the dose-response curve fit and considered to be the 
“transition pH” at which HA refolds from a closed to an open conformation.  Reported 
transition pH values are averages from independent experiments. 
2.3  Results 
2.3.1  Previously identified HA mutants with altered activation pH 
Linking phenotypic changes to genetic changes creates the ability to probe the 
structure-function landscape and identify residues, or areas of the protein structure, that 
are involved in the conformational refolding of fowl-plague virus hemagglutinin (FPV 
HA).  Previously, research in our lab developed a flow cytometry assay where HA 
refolding is decoupled from membrane fusion and can conveniently be quantified by 
immunofluorescent staining and flow cytometry (Figure 2.4).58  The development of this 
flow cytometry assay for HA refolding allowed for the construction of three separate 
libraries by error-prone PCR and the ability to use fluorescence-activated cell sorting 
(FACS) to isolate HAs whose neutral pH conformations were either stabilized or 
destabilized with respect to wild-type hemagglutinin (Figure 2.5).  Mutants from each of 
the three libraries were isolated and their genes sequenced to identify mutations that 
may or may not be responsible for pH sensing (Table 2.1).  This chapter will analyze 
these previously identified mutations to try and identify individual mutations responsible 
for pH sensing and how these mutations likely affect the structure-function relationship 
of hemagglutinin. 
 In the previously developed assay, a set of monoclonal antibodies is used to 
assess HA refolding where two antibodies, HC58 and anti-c-myc (9e10) (when HA2 
19 
 
Figure 2.3  HA refolding decoupled from membrane fusion.  A) HA expressing HEK293 
cell monolayers are detached from culture plates using 0.05% Trypsin-EDTA.  Cells are 
then transferred to 1.5 mL microcentrifuge tubes for washing and immunofluorescent 
labeling steps.   B)  Schematic of surfaced expressed HA refolding and 
immunofluorescent staining flowing 5 minute pH pulse.  At neutral pH (left), HA is in its 
metastable neutral conformation with HC2 and HC58 epitopes available for antibody 
binding (upper right) while the c-myc epitope is not.  Following the pH pulse and 
irreversible conformational change, HC2 and c-myc epitopes are available for 
immunofluorescent staining while HC58 is not (bottom left). C) Crystral structure of H7 
HA showing locations of HC2, HC58 and c-myc eptiopes.   D) Following 
immunofluorescent staining, cells are sorted (library) or analyzed (characterization) for 
refolding with a flow cytometer.  For all HA depictions (B and C), only monomers are 


















Figure 2.4  pH pulse experiment for HA refolding.  HA-expressing cells (red, upper left) 
are subjected to a 5-minute pulse of pH buffer (pH 4.6 to 6.4 in increments of 0.2 pH 
units).  Following the 5 minute pulse, cells are quenched with pH 7.4 buffer to stop any 
additional refolding.  Cells are then labeled with a conformation specific mouse antibody 
(HC58, specific for the neutral pH conformation) for 45-60 minutes at 4°C.  The labeled 
cells are then washed once and labeled with an anti-mouse second antibody for 45-60 







Figure 2.5    Previous directed evolution of HA.  A)  Design of three separate libraries to 
alter the conformational stability of HA.  The top two library depictions illustrate that 
libraries were sorted following a higher pH pulse step to activate only destabilized HA.  
The bottom library design was more complicated.  The library was initially pulsed at pH 
5.2 to activate wild-type and destabilized HA.  Thermolysin was then used to cleave the 
fusion peptide, eliminating the c-myc epitope signal.  The library was then re-pulsed with 
pH 4.8 buffer to activate stabilized HA.  B)  Top panel represents the pH 5.6 library and 
the bottom panel represents the pH 6.0 library before and after 3 rounds of sorting.  C)  
pH 4.8 library population following pH 5.2 pulse (right), thermolysin cleavage (middle), 
and pH 4.8 pulse (left).   Data in parts B and C reprinted from Lee, Jeong H. 
“Engineering and Characterization of Influenza Hemagglutinin Properties in Mammalian 




















11-20 is replaced with the c-myc epitope) (Figure 2.3C), only detect the neutral and low 
pH conformations, respectively, while HC2 binds irrespective of HA conformation.66  HA-
expressing cells are first trypsinized from the culture dish using 0.05% Trypsin-EDTA 
and transferred to 1.5 mL microcentrifuge tubes for the washing and labeling steps.  At 
this point, cells are kept as close to 4°C as possible.  HA-expressing cells are washed 
twice with PBS+0.1% BSA.  Following the second wash step, a 5 minute pH pulse is 
applied to induce HA refolding.  Citrate buffers with different pHs ranging from 4.6 to 6.4 
in increments of 0.2 units were used to subject the HA-expressing cells to a 5 minute pH 
pulse to induce HA refolding.  Following the 5 minute pH pulse, cells were quenched 
with pH 7.4 PBS.  After the pH pulse and quenching with pH 7.4 buffer, the cells were 
labeled with a conformation specific antibody.  In the previously performed library 
selections, anti-c-myc (9e10) was used to identify exposure of the fusion peptide upon 
HA refolding.  In this work, the conformation specific antibody, HC58, specific for the 
neutral HA conformation was used.  Cells were incubated with primary antibodies for 
45-60 minutes, then washed once and labeled with a fluorescent secondary antibody.  
Both 9e10 and HC58 are mouse monoclonal antibodies, so a anti-mouse secondary 
antibody was used to detect binding of the primary antibody to HA.  Again, cells were 
incubated with the secondary antibodies 45-60 minutes on ice and then washed once to 
remove any unbound antibody. The immunofluorescently labeled cells were then run on 
a flow cytometer to analyze for HA refolding. 
A number of studies using various biochemical assays have demonstrated that 
wild-type hemagglutinins are typically fully refolded by pH 5.2 and transition from a 
neutral conformation to the extended, low pH conformation around pH 5.4-5.5. Previous 
work was performed to try and isolate HAs that were destabilized compared to wt HA. 
Two HA libraries, HA3.2 and HA3.3, were created and exposed to a five minute pH 
pulse of either pH 5.6 or 6.0, respectively (Figure 2.5 A and B).  A brief pulse at 
elevated pH allowed for any library members with destabilized HA to refold prior to 
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library members that may be expressing wt-like or stabilized HA.  Three rounds of 
fluorescence-activated cell sorting (FACS) were used to enrich a population of HA that 
was destabilized with respect to wild-type HA.  Following the third round of sorting, the 
two destabilizing libraries had been enriched to the point where 96% of HA3.2 and 88% 
of HA3.3 had been activated by their target pH (Figure 2.5 B).  Mutants from these two 
libraries were isolated and mutations were identified by sequencing.  
While there are numerous studies where investigators have either created, or 
found, destabilizing hemagglutinin mutations there are very few reports of mutations 
that stabilize HA in the presence of low pH.46  Even though Thoennes et. al. report on a 
few mutations that appear to be stabilizing (H171Y and  K512A), the authors were not 
explicitly looking for stabilizing mutations but rather exploring the effect of ionizable 
residues around the fusion peptide to trigger HA refolding.46  To identify mutations that 
had a stabilizing effect, the HA3.4 library was first pulsed at pH 5.2 to activate all 
destabilized and wild-type-like mutants. Refolded proteins with an exposed fusion 
peptide with the c-myc epitope were then susceptible to proteolytic cleavage by 
thermolysin,58; 68 making their conformational change undetectable.  Following the 
thermolysin digest with another pH pulse at pH 4.8 allows any stabilized mutants to be 
activated and expose their fusion peptide along with the c-myc epitope for fluorescent 
staining (Figure 2.5 A and C).  Flow cytometry shows that after the first pulse at pH 5.2, 
a significant population is positive for c-myc; however, following cleavage with 
thermolysin, the population seen in the left panel of is no longer present in the middle 
panel.  Finally, reapplying another pulse with pH 4.8 buffer activates another significant 
population presumably expressing stabilized HA.  Library clones were isolated after two 
rounds of sorting and mutations contributing to a stabilized HA conformation were 
identified.  This chapter will focus on the identifying mutations that are responsible for 
the altered phenotypes selected for in the previous directed evolution experiments that 
have just been described. 
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2.3.2  Identification of Destabilizing Mutations 
To further understand which mutation(s) were responsible for destabilization of 
the hemagglutinin trimer, and to better understand what mechanism(s) drives HA 
refolding, individual mutations were analyzed.  Five representative clones from the 
HA3.2 library and three clones from the HA3.3 library were previously isolated and 
sequenced following the three rounds of sorting to identify a set of mutations that may 
have contributed to the destabilization of the protein.  From the sequenced clones of the 
mature HA3.2 library, a total of ten unique mutations were identified out of fourteen total 
mutations (Table 2.1).   The three sequenced clones from the HA 3.3 library produced 3 
unique mutations out of 7 total mutations.  Interestingly, while both the HA3.2 and 
HA3.3 library were designed to identify destabilized HA, the two distinct libraries only 
shared one common mutation D166G.   
The panel of mutations was thoroughly analyzed by creating hemagglutinin 
trimers with individual mutations using site-directed mutagenesis.  To capture the 
behavior of wild-type HA, the c-myc epitope in the fusion peptide was not used to 
assess HA refolding, but rather the conformationally specific antibody, HC58.  HC58 
binds to HA in its neutral-pH conformation at interfaces between HA1 headgroups of 
two monomers; therefore as the headgroups dissociate upon HA refolding HC58 
binding is abolished.66  Flow cytometry was used to measure the median fluorescent 
intensity of the HC58 binding to HEK293 expressing cells following pH pulses in a range 
of pH around the expected pH of activation.  The median fluorescent intensity (MFI) was 
plotted against pH and a dose-response curve was fitted to the plots (Figure 2.6).   An 
EC50 value was extracted from the plots and used as the transition/activation pH for 
that mutant protein.   
From the flow cytometry results two mutations each from the 5.6 and 6.0 pH 
libraries appear to destabilize HA.  I96M and W243S, originating from the HA 3.2 library
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Figure 2.6  HA normalized pH transition curves.  HEK293 cells expressing HA point 
mutations were exposed to buffered solutions at a range of pH spanning the expected 
transition pH.  Viable expressing cells, gated on light scattering, were analyzed for 
refolding by flow cytometry using conformation specific antibody, HC58, and median 
fluorescence was plotted against pH. Shown here are representative pH transition 
curves for mutant D247N (blue), wt HA (black) and G365C.  EC50 values, referred to in 






(pH 5.6 selection pressure), appear to be slightly destabilizing (Table 2.2).  Meanwhile, 
two mutations from the HA 3.3 library, G237R and G365C, are significantly destabilizing 
(Table 2.2).  Two of the three clones isolated from the HA3.3 library contained both 
G237R and G365C mutations, while the third clone from the HA3.3 contained D166G 
and G365C mutations with the D166G mutation not contributing to the high pH 
activating phenotype. Meaning G365C is likely solely responsible for the destabilized 
protein.   The double mutation of G237R and G365C likely made HA highly destabilized. 
2.3.3  Identification of Stabilizing Mutations 
After analyzing individual mutations from the HA3.4 library clones the 
stabilization of HA in response to lower pH appears to be due to a single mutation, 
D247N.  Interestingly, a second stabilizing mutation was also found in the HA3.2 library 
which was screened after a pH pulse of 5.6.   D247N has an activation pH midpoint of 
4.8 about 0.6 less than wild-type hemagglutinin (Table 2.2).  The S429P mutant was 
further stabilized by about 0.4 pH units compared to wild-type HA making this mutation 
moderately stabilizing.  These mutations will be further discussed below. 
2.4  Discussion 
Here we report the use of directed evolution to identify novel mutations in fowl 
plague hemagglutinin that contribute to either a stabilized or destabilized neutral pH 
structure.  Previous work to better understand HA refolding has relied mainly on two 
approaches, selection of virus variants and rationally designed point mutants35; 46; 47; 60; 
64; 65; 69; 70; 71; 72.  While these approaches have proven successful in their ability to isolate 
HA variants that are either acid-stable or undergo the irreversible conformational 
change at elevated pH, they are intrinsically limited by the constraints of nature.  HA 
mutants isolated in amantadine resistance experiments, where amatadine hydrochloride
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Table 2.2  Transition pH for individual mutants 
 
Note:  Highlighted rows represent mutations that have a transition pH that is significantly 
different than wild-type hemagglutinin.  Green represents stabilizing mutations, orange 





Mutation Selection pH Transition pH (EC50) 
wild-type - 5.545 ± 0.08 
D93S 4.8 5.51 ± 0.04 
Y155F 4.8 5.54 ± 0.05 
A168V 4.8 5.56 ± 0.16 
D240Y 4.8 5.35 ± 0.05 
D247N 4.8  4.83 ± 0.18 
E462Q 4.8 5.65 ± 0.08 
I96M 5.6 5.79 ± 0.001 
G142D 5.6 5.51 ± 0.05 
D166G 5.6/6.0 5.50 ± 0.09 
V188G 5.6 5.43 ± 0.22 
Y218H 5.6 5.49 ± 0.10 
W243S 5.6 5.67 ± 0.15 
L407A 5.6 5.61 ± 0.02  
S429P 5.6 5.06 ± 0.07 
G237R 6.0 6.30 ± 0.16 
G365C 6.0  6.09 ± 0.17 
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affects the intracellular pH,65; 66 have been chosen based on the ability of cells treated 
with amantadine to produce viral particles capable of lysing cells.64; 65  These mutants 
are therefore somewhat limited in the sequence space they can sample because of the 
necessity to retain membrane fusion activity and viral infectivity.  Studies employing 
site-directed mutagenesis often changed residues based on:  locations previously 
identified as affecting pH-sensing65, sequence alignment46; 60; 71, structurally interesting 
locations such as the fusion peptide or fusion peptide pocket35; 72, or a combination of 
these.47  Either way, previous studies have been limited because of selections based on 
membrane fusion or sequence alignments where highly conserved amino acids are 
typically not changed. 
Directed evolution uses repeated rounds of selection to quickly enrich rare 
populations and has been used to successfully engineer a variety of proteins with 
improved fitness from single-chain antibodies73 to enzymes that can be used as 
biocatalysts.74  Using error-prone PCR to introduce mutations into the gene for FPV HA 
removed the natural constraint of fusion competency allowing for residues that are 
normally highly conserved across all HA subtypes to be mutated. Out of the sixteen 
unique mutations found in previous directed evolution screens, two of the mutations 
(G365C and W243S) were found at residues that are conserved across all HA subtype 
consensus sequences.75; 76   To our knowledge, of the 16 mutations found screening the 
library of mutated H7 HAs, 15 have never been identified as mutations affecting pH 
sensing and the sixteenth mutation, G365C, was found to be stabilizing in a previous 
study.71 
As previously mentioned, four mutations (I96M, G237R, W243S, and G365C) 
were found that destabilized the neutral conformation of HA. Two of the mutations are 
located at residues that are conserved among all HAs (W243 and G365) and three of 
the four mutations are located in the HA1 headgroup (Figure 2.7).  The majority of 
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Figure 2.7  Structural locations of pH sensing mutations.  A)  Side image of 
hemagglutinin trimer with mutations that affect pH-sensing shown as spheres and color-
coded according to Table 2.2.  Coordinates used in the analysis are from PDB file 
1HGF77 and the images were generated using PyMol software (http://www.pymol.org). 
B) Top-down image of the HA trimer with same pH-sensing mutations displayed and 
















previously identified pH-sensing mutations have been located in the HA2 subunit with 
very few mutations found to sense pH in the HA1 headgroup.35; 46; 47; 64; 65; 70  The I96M 
mutation allows HA to undergo its acid-induced refolding ~0.3 units higher than wild-
type FPV HA most likely due to disrupting the side chain packing.  In the neutral pH 
conformation, the smaller side of isoleucine packs tightly into a small pocket created by 
three loops of HA1:  T64 to D66, D93 to E97, and M274 to V282 (Figure 2.8).  The 
additional length of the methionine side chain may have trouble fitting into this small 
pocket and that likely destabilizes the surrounding contacts.  One contact that is likely 
altered as a result of Ile-Met substitution is the hydrogen bonding between Q277 and 
E411.  E411 has been previously identified as a residue that makes critical contacts 
between the B-loop of HA2 and surrounding residues in the prefusion conformation and 
that B-loop rearrangement is a critical step in the loop-to-helix transition that occurs in 
HA2.60  Taken together, it seems most plausible that steric hinderances caused by the 
methionine side chain eventually lead to disruption of hydrogen bonds between E411 
and Q277, which allows for the neutral pH structure to become destabilized more 
readily. 
While the structural implications of I96M are somewhat ambiguous, the effects of 
a Gly-to-Arg mutation at HA1 237 seem more straightforward.  G237R raised the pH at 
which HA undergoes its structural transition by 0.8 units, similar to that for G365C.  Glu-
237 is located near the HA1-HA1 interface and is next to Arg-238.  Introducing a second 
arginine residue close to the HA1-HA1 interface likely contributes to long-range 
electrostatic interactions that destabilize the interface.  Two positively charged arginines 
next to each other and located near positively charged residues on the apposing HA1 





Figure 2.8  I96M mutation structural implications.  Ile-96 is shown as ball-and-stick in 
dark blue and the Ile-96-Met mutation is shown as ball-and-stick also, and colored 
orange with the sulfur of the side chain yellow. The I96M mutation was modeled using 
Swiss pdbViewer and the rotamer with the best score was chosen. Possible interactions 
with the loop (colored lime green) containing Gln-277 may disrupt its interaction with 
Glu-411 of the HA2 B-loop ultimately destabilizing the neutral pH structure. 





further destabilize the neutral pH conformation (Figure 2.9).  The pKa of histidine is 6.0 
and Mittal et. al. report that the pKa for each hemagglutinin monomer is between 5.6 
and 5.7 indicating that histidine residues could play an important role in pH sensing.78  
Thus, while it is impossible to precisely know the pKa of H219, it likely becomes 
protonated providing additional positive charge at the same interface of the G237R 
mutation.  The additional charge provided by the mutation, as well as the positive 
charge associated with the protonation of His-219 as the pH drops, disrupts the HA1 
interface sufficiently enough for the headgroups to dissociate and HA2 to refold into the 
extended coiled coil, low pH conformation.     
Arguably, a more interesting mutation to be identified as being responsible for the 
destabilization of the neutral pH conformation is W243S.  W243S elevated the transition 
pH of HA by ~0.2 but W243 is a conserved residue among all HA subtypes and is 
located at an interface between HA1 and HA2 of an adjacent monomer.  W243 fits into 
a hydrophobic pocket created mainly by the HA1 headgroup and Val415 of the B-loop of 
the neighboring HA2.  As previously mentioned, the B-loop of HA2, which under goes 
the loop-to-helix transition upon activation, has been proposed to transition to a relaxed 
state under acidic conditions prior to undergoing its irreversible conformational 
change.79  When W243 is occupying the hydrophobic pocket in the metastable 
structure, Val415 is unable to occupy the hydrophobic pocket of W243 thus maintaining 
the prefusion conformation (Figure 2.10).  However when serine is introduced in place 
of W243, the hydrophobic pocket is unoccupied and valine is able to position its side 
chain in the hydrophobic pocket allowing the B-loop to adopt its “relaxed” form prior to 
the loop-to-helix transition.  The proposed ability of valine to occupy the hydrophobic 
pocket would allow HA2 to more readily undergo its acid-induced conformational 




Figure 2.9  G237R electrostatic interactions.  The G237R mutation was modeled using 
Swiss pdbViewer and shown as green spheres.  R238 (purple) of the same monomer, 
as well as the locations of K217 and H219 (gray) of FPV HA, are also shown as 
spheres.  The proximity of these positively charged residues likely contributes to 




Figure 2.10  Effect of W243S mutation on HA structure and pH sensing.  A)  Structural 
rendering of W243 occupying a hydrophobic pocket in the neutral HA0 structure (PDB 
1HA0).80  Val-415 does not readily occupy the hydrophobic pocket at neutral pH when 
W243 is present.  B)  The mutation W243S clears way for Val-415 to move into the 
hyrodrophobic pocket thus allowing the B-loop of HA2 to swing outward into a “relaxed” 
conformation, primed to undergo the loop-to-helix transition that is essential in the 
spring-loaded refolding model.  The two HA2 structures shown are at pH 8.1 (orange, 
PDB 3QQB) where the B-loop is still closely packed with the α helix, and at pH 5.3 
(cyan, PDB 3QQO).  The pH 5.3 structure was stabilized in the closed conformation by 
H2-HA2R106H and shows the B-loop adopting a “relaxed” position assumed to be an 
intermediate structure before undergoing the loop-to-helix transformation.60       
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Results in this study show that the one of most destabilizing mutations found 
G365C, and together with D247N, had the largest deviation in transition pH from 
type HA (~0.6-0.7).  Gly-365 is located at the end of the fusion peptide in the 
proximal region of HA2 near where HA1 and HA2 are covalently attached via a 
bond between C14 and C479.  Substitution of Gly-365-Cys places an additional 
cysteine less than 12Å away from the HA1-HA2 disulfide ( 
Figure 2.11).  We propose that G365C interferes with the native disulfide in at 
least one HA monomer, causing a gross displacement of that HA1 head group leading 
to a loss, or disruption, of all stabilizing contacts in the trimer head group.  Previous 
work examining disulfide bond formation in HA found that mutant HAs with a C14S or 
C479S mutation failed to form disulfide bonds with any of the native cysteine residues of 
HA1, but confirmed that a small portion of mutants were transported to the cell surface 
in a non-native conformation.81  The formation of a new disulfide bond between C14 and 
G365C would likely only occur in a few monomers given the propensity of HA to form 
native disulfide bonds.  Formation of new disulfides in only one or two monomers would 
destabilize the entire trimer while still allowing the refolding of the other monomer(s) and 
exposure of the c-myc epitope that was used in the directed evolution work to identify 
destabilized HA, from which the G365C mutation was isolated.  Interestingly, our flow 
cytometric data is in direct conflict with a previous study that made the same mutation in 
another H7 variant, A/Netherlands/219/03 (H7N7).71  The study by Ilyusina et. al., found 
that substituting Cys for Gly232 resulted in a stabilized HA that refolded 1.0 point below 
the pH of the wild-type A/Netherlands/219/03 HA.  While the different HA variants may 
explain some of the differences between the previously reported results and ours, it is 
likely not enough to explain a ~1.7 pH difference in transition pHs between two closely 
related HAs.   
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Directed evolution was also used to identify mutations that stabilized 




Figure 2.11  G365C mutation and disulfide bonding.  G365C is shown as magenta 
spheres near the native disulfide that covalently links the HA1 and HA2 subunits.  The 
destabilizing affect arising from the G365C mutation may be due to disulfide bond 
formation between the new cysteine of HA2 and Cys-14 which is one-half of the native 
disulfide.  A new disulfide would likely shift the entire HA1 headgroup therefore 
destabilizing the entire protein. 
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conformational change.  Two mutations have been identified as stabilizing the neutral 
conformation, D247N and S429P. However, only D247N was found via screening of the 
4.8 pH-pulsed library.  S429P was identified in clone HA3.2.5 along with two 
destabilizing mutations I96M and W243S, supporting the idea that multiple mutations 
with in HA can be cumulative.65  S429P was found to stabilize the trimeric structure by 
0.4 units from the wild-type transition pH.  S429P is located near the membrane distal 
segment of the long α-helix of HA2. A serine to proline mutation likely stabilizes the 
neutral pH conformation through interactions between the large α helix of HA2 and the 
neighboring B-loop.  In H2 HA, Phe-405 of the B-loop packs tightly against Phe-430 of a 
neighboring HA2 stabilizing the neutral pH structure.60  In H7 HA, and specifically for 
Rostock/FPV HA, there is no aromatic side chain at position 430 or adjacent residues in 
a neighboring HA2 to make an aromatic stack with the conserved Phe-405 to stabilize 
the structure.  The aliphatic ring structure of a proline substitution provides additional 
hydrophobic contacts with Phe-405 compared to serine providing a stabilizing force to 
keep the HA in an acid-stable conformation(Figure 2.12).82  D247N stabilized the 
transition pH of HA by 0.6 and is located in the HA1 headgroup at the HA1-HA1 
interface.  The side chain of Asp-247 is positioned directly across from Glu-414 of an 
adjacent HA2 subunit, creating a charge repulsion that destabilizes the neutral 
conformation to some extent and is a critical component of the metastable conformation 
(Figure 2.13).  Substitution of a neutral asparagine residue is not only a conservative 
mutation, but it acts to eliminate the charge repulsion between D247 and E414‟ 
stabilizing the neutral conformation of HA.   
Interestingly, all of the destabilizing mutations were found in multiple clones 
except for I96M and each of the stabilizing mutations only appeared in one clone.  Of 
the six mutations identified in this study, all but G365C and S429P were located in the 
HA1 headgroup.  The locations of the mutations found through this directed evolution 




Figure 2.12  Stabilization of B-loop by S429P mutation.  The addition of a aliphatic ring 
by the mutation of Ser-429 to proline allows the aromatic residue of Phe-405 of the B-
loop to be stabilized in a ring packing manner.  The S429P mutation was modeled in 










Figure 2.13  Asp-247-Asn mutation relieves electrostatic repulsion.  In the native HA 
structure the negatively charged side chain of Asp-247 is directly opposed by the 
negatively charged side chain of Glu-414 and separated by roughly 4Å.  The proximity 
of both negative charges would destabilize the HA1-HA1 interface priming it for 
refolding.  By substitution of Asp with Asn, that charge repulsion is relieved stabilizing 






refolding of hemagglutinin.  Other studies have proposed that the B-loop of HA2 and 
regions of HA1 that interact with this loop are critical for controlling the pH of fusion.35; 60  
Our results tend to agree with this finding based on the number of mutations that likely  
interact with the B-loop of HA2 in some capacity.  We propose, more specifically, that it 
is the HA1 headgroup that acts as the primary pH-sensing mechanism and HA1-HA1 
interactions must be sufficiently interrupted by the increasing concentration of protons 
within the endosome, so that HA1 headgroups dissociate allowing the HA2 subunit to 
undergo its conformation rearrangement.   The total displacement of HA1 globular 
domains is in agreement with a previous computational study that showed complete 
dissociation of the head groups is the most energetically favorable pathway to the low 
pH, irreversible conformation.63  Through directed evolution, mutations were made to a 
few highly conserved residues that had previously not been explored for pH-sensing 
and the location of both stabilizing and destabilizing mutations within the HA1 
headgroup provide clues to HA1 acting as the primary pH sensor that controls 
hemagglutinin switching.  
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Chapter 3 :  Engineering and characterization of an improved chimeric 
adhesive switch via directed evolution using yeast surface display 
3.1  Introduction 
Nature has evolved to include many complex processes that require 
sophisticated proteins capable of controlling cellular signals and functions.  This is often 
accomplished through allosteric regulation where output signals are modulated in an 
„on/off‟ fashion by the presence or absence of effector molecules (e.g., small molecules 
or ligands).  Allosteric regulation was first proposed fifty years ago as a way to describe 
proteins in metabolic networks that regulated the production of metabolites and revolved 
around two core concepts which haven‟t changed; first, the effector binding site is 
spatially distinct from the active site, and, second, the effect is entirely due to 
conformational changes within the protein structure.10 
These key concepts have been the basis for a number of different approaches to 
engineering functional molecules for use in sensing, diagnostic or therapeutic functions.  
Controlling transgene networks for the treatment of diseases is reliant upon precise 
control of genes at the transcription and translation levels with small molecules, such as 
siRNA, or gene switches.83; 84  One such example of a gene switch is nuclear hormone 
receptor, hERα, which had its ligand selectivity engineered from its natural ligand 17β-
estradiol to a synthetic ligand 4,4‟-dihydroxybenzil (DHB) using site saturation 
mutagenesis and directed evolution. 85  Protein switches have also been created for 
diagnostic and sensing applications by fusing heterologous genes together to couple 
two disparate protein functions in a modular fashion.  Examples of modular switches 
created by varying degrees of domain insertion include fusions of TEM1 β-lacatamase 
(BLA) and maltose binding protein (MBP), photoprotein (AEQ) and sulfate-binding 
protein (SBP), and between the photoactive LOV2 domain of Avena sativa and E. coli 
trp repressor.86; 87; 88   Until recently, proteins  such as GFP, luciferase, dihydrofolate 
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reductase (DHFR) and β-galactosidase have been heavily relied upon in engineering 
protein switches as they provide simple phenotypic screening and selection 
strategies.14; 15   
Recent work in our lab has demonstrated the ability to modulate cellular 
adhesion between the αL inserted (I) domain and an intercellular adhesion molecule-1 
(ICAM-1)-coated surface under shear flow by the presence or absence of an effector 
peptide.89   The allosteric rearrangement within the I domain was exploited to make a 
functional switch by fusing the EF3 and EF4 hands of calmodulin to the N- and C-
termini of the I domain, respectively (Figure 3.1 D).   
3.1.1  I domain 
In an innate immune response, inflammation is a front-line defense against 
infection, injury or trauma.  Inflammatory responses typically only last a few days and 
include a wide array of cell types, receptors, selectins, and chemokines.  While 
inflammation tends to be a transitory response, prolonged inflammation is responsible 
for a number of pathological and clinically relevant conditions such as rheumatoid 
arthritis, Crohn‟s disease, and transplant rejection where prolonged inflammation leads 
to tissue and organ damage. Among the many players of the inflammation cascade 
arguably the most important are integrins.   
The inflammatory cascade begins when blood vessels dilate and flow is 
slowed.90  Inflammed endothelial cells express E- and P-selectin on their surface, which 
in conjunction with reduced flow allows leukocytes expressing P-selectin glycoprotein 
ligand 1 (PSGL1) to transiently tether to the vasculature. The transient interactions 
between endothelial cells and leukocytes are mediated by the high on- and off-rates of 
the selectin-ligand interactions; this selectin-mediated rolling allows for intracellular 
signaling to occur within the leukocyte via chemokine binding to G-protein coupled 
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Figure 3.1  Role of αL I domain in LFA-1 and a fusion protein switch. A, B and C)  
Activation of LFA-1 from a bent, closed, low-affinity conformation (A), to an extended, 
closed, low-affinity conformation (B, left).  An inside-out signal is transduced up the β-
leg resulting in alteration of the β I-like domain (blue domain) MIDAS allowing Glu-310 
to bind and pull down the α7 helix of the I domain (pink domain, B right).  In nature, the 
bond between ICAM-1 and the αL I domain is strengthened by force (C).  D)  The 
pulling down of the α7 helix is mimicked in our switch construct by the binding of the 
EF3 and EF4 hands of calmodulin to a peptide of smooth muscle myosin light chain 
kinase (smMLCK, purple helix).  The original chimeric fusion between I domain and the 
EF3 and EF4 hands of calmodulin, prior to any mutagenesis or directed evolution, is 
referred to in this dissertation as “wild-type switch.” Upon binding, the α7 helix (orange) 
is displaced downward allowing for the adoption of a high affinity conformation by the I 












receptors (GPCRs).91  Activation of GPCRs by chemokines induces a complex signaling 
network, which at this time is not completely understood, 91 but that activates integrins 
by actin-binding proteins such as talin-1, kindlin, or filamin.11; 91  Binding of integrin 
cytoplasmic domains by actin-binding proteins separates the α and β cytoplasmic 
domain tails inducing a „switchblade-like‟ conformational rearrangement into an 
extended, primed conformtation in a process termed „inside-out signaling‟ (Figure 3.1C). 
11; 90; 92   Integrin avidity, the total adhesiveness of the ligand-protein interaction, is 
composed of integrin affinity for its ligand and the valency (number of contacts) between 
the protein and ligand.  Once activated, integrins facilitate leukocyte firm adhesion to the 
endothelium followed by crawling and then paracellular and transcellular transmigration 
into the site of inflammation to carry out its immunological activity. 91  
Lymphocyte function-associated antigen-1 (LFA-1) is probably the most widely 
studied and and well characterized member of the integrin family.  It is a heterodimeric 
transmembrane protein composed of noncovalently associated α and β subunits.  While 
each subunit is large and complex, the ligand binding site is contained solely within the 
180 amino acid inserted (I) domain of the αL subunit of LFA-1 (αLβ2, CD11a/CD18) 93.  
The crystal structure of the αL I domain reveals a central hydrophobic pocket composed 
of six β-strands adopting a Rossman fold surrounded by 7 amphipathic α helices.9; 93; 94 
A Mg2+ ion is located at the “top” of the crystal structure as part of a metal ion-
dependent adhesion site (MIDAS), and is ligated by five residues, D137, S139, S141, 
T206 and D239 (Figure 3.2).93  LFA-1 binds intercellular adhesion molecules (ICAMs), 
of which it has the highest affinity for ICAM-1.11; 93   ICAM-1 binds to the I domain of 
LFA-1 through coordination of an acidic residue (Glu34) to the MIDAS of I domain, 
which is surrounded by a ring of hydrophobic residues in both the ICAM-1 and I domain.  
A salt bridge between Glu-241 and Lys-39 of I domain and ICAM-1, respectively, is also 
crucial for ligand binding.93  The exposure of the MIDAS is in conjunction with the axial 
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Figure 3.2  αL I domain.  A)  Low-affinity, “closed”, conformation of αL I domain.  The 
magnesium ion of the MIDAS (metal ion-dependent adhesion site), in the top portion of 
the structure, is colored in yellow.  Residues coordinating the Mg2+ of the MIDAS are 
shown as ball and sticks, where oxygen atoms are red and nitrogen atoms are blue.  
Glu-310 acts as a pseudo-ligand for the β2 I-like domain and ligates the Mg2+ of the I-
like MIDAS in a similar fashion to Glu-34 of ICAM-1 to the MIDAS of the αL I domain.  
B)  High affinity, “open”, conformation I domain structure.  Again, the Mg2+ of the MIDAS 
is shown as a yellow sphere.  The α7 helix has been displaced downward by 10Å 
compared to the low affinity conformation.  Additionally, the coordinating residues have 
also rotated as a result of the allosteric rearrangements due to the motion of the α7 helix 
and are now in a position to facilitate ICAM-1 binding.  C)  ICAM-1 bound to the I 










downward movement of the α7 helix of I domain by about 10 Å.  The downward 
movement of the α7 helix of the I domain acts as a pulley causing a rearrangement of 
the metal ion-dependent adhesion site (MIDAS) drastically altering the affinity for the 
ligand, ICAM-1.9; 11; 92; 95  This downward movement toward the β I-like domain also 
allows for interaction between Glu-310 of the linker between the α I domain and β 
propeller domain and the β I-like MIDAS.  This conformational interaction between the 
different subunits allows LFA-1 to transduce signals bidirectionally through the different 
domains.9; 92; 93; 94; 96  This allosteric interaction between the I domain and the I-like 
domain in the β subunit makes the I domain an ideal candidate for engineering a novel 
molecular switch.   
The allostery of the I domain can be coupled with other protein domains to create 
a chimeric protein switch.  Additionally, the flexibility seen within I domain with the 
proximity of its N- and C-termini makes I domain very suitable for circular permutation.  
Circular permutation, coupled with allosteric proteins, gives engineers a powerful 
combination to create novel molecular switches with increased affinities or functions 14; 
86; 97.   Previous work has demonstrated that the individual EF-hands of each calmodulin 
subdomain can solubly recombine in the presence of the target peptide, smooth muscle 
myosin light chain kinase (smMLCK).98  Fusion of the EF-hands to the termini of the I 
domain likely produces a disruption in the allosteric region of the I domain due to the 
repositioning of the α7 helix upon binding of the EF3 and EF4 hands to smMLCK 
peptide leading to a three-fold increase in adhesion (Error! Reference source not found. 
D).89  Here we show that through focused mutagenesis on the allosteric region of the I 
domain and directed evolution a near twenty-fold improvement in switch activity was 
achieved.  This improvement in switch activity has resulted in mutant switches that were 
effectively “on/off” in their behavior.      
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3.2  Materials and Methods 
3.2.1  Yeast strains and plasmid 
S. cerevisiae EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ1 
his3Δ200 pep4::HIS3 prb1_1.6R can1 GAL) cells were transformed with pCT302-
derived vectors allowing for selection under Trp- and Ura- conditions and surface 
expression of proteins under the galactose inducible GAL1,10 promoter.99  pCT302 was 
used as the expression vector for all experiments except for circular permutation and 
fusion constructs were cloned in using NheI and BamHI restriction sites.  Routine sticky-
end restriction enzyme digestion and ligation reactions were performed as follows.  
Briefly, 10 μL of purified plasmid DNA was digested using 1 μL (20 Units) of NheI-HF 
(NEB) and 1 μL (20 Units) of BamHI-HF(NEB), 4 μL of NEB CutSmart buffer (10X), 0.4 
μL BSA (100X) and 23.6 μL of dH2O in a total reaction volume of 40 μL.  The 
preparative double digest was placed in a 37°C water bath for 2-3 hours.  The reaction 
was stopped with 10X stop buffer (50% (w/v) glycerol, 0.1 M EDTA (pH 7.5), 1% (w/v) 
SDS, and 0.1% (w/v) bromophenol blue).  Digested DNA was analyzed by gel 
electrophoresis and the correctly sized bands were excised and purified using the 
Promega Wizard gel purification kit following the manufacturer‟s instructions.  Ligation 
reactions contained 3 μL of purified linearized vector, 6 μL of purified DNA to be 
inserted, 2 μL of T4 Ligase buffer, 8 μL of dH2O and 1 μL of T4 Ligase.  Ligation 
reactions were carried out at 16°C overnight and the following day, 2 μL of ligation 
reaction was used to transform E. coli. Use of NheI and BamHI restriction sites allows 
two epitope tags (HA and c-myc) on either side of the gene of interested to be 
expressed in the ORF.  For the circular permutation library, the AfeI restriction site was 
inserted into pCT302 via PCR on the C-terminal side of NheI and the N-terminal side of 
BamHI, respectively, allowing for blunt-end cloning and termed vector pCT-JVP (primer 
sequences can be found in Appendix 6).  Briefly, the PCR reaction to insert the AfeI 
restricition sites used 5 units of Taq DNA polymerase (NEB) with 5 μL of 10X standard 
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Taq buffer, 200 μM dNTPs, roughly 50 ng of plasmid DNA, and 0.15 μM of each primer.  
PCR cycles used were as follows: initial denaturation at 95°C for 2 minutes, then 30 
cyles of 95°C for 30 seconds, annealing at 62°C for 30 seconds, extension at 68°C for 
50 seconds, followed by a 5 minute final extension at 68°C.  The PCR product was 
inserted into the TA-cloning vector, pCR2.1, using the TOPO TA cloning kit following the 
manufacturer‟s instructions (Invitrogen).  The gene fragment containing the newly 
inserted AfeI restriction sites was then transferred from the cloning vector to a linearized 
pCT302 vector using restriction enzyme digestion and ligation.  The AfeI restriction sites 
were confirmed by gel electrophoresis and sequencing.  Yeast were grown in the semi-
defined media SD-CAA (20g/L dextrose, 6.7 g/L yeast nitrogen base without amino 
acids, 5.4 g/L Na2HPO4, 9.7 g/L NaH2PO4·H2O, and 5 g/L CAA) at 30°C overnight.  The 
following day, expression was induced by subculturing at an OD600 of 1 and grown 
overnight in SGR-CAA (same as SD-CAA expect 2% (w/v) dextrose is replaced with 2% 
galactose and 2% D-Raffinose). 
3.2.2  Magnetic-activated Cell Sorting (MACS) 
Yeast were grown and induced as previously described.  Following overnight 
induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were transferred to 
microcentrifuge tubes for washing and immunostaining.  108 yeast were washed twice 
with 1 mL of PBS(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) 
supplemented with 1 mM MgCl2 and 0.1% BSA.  A MACS LS column (Miltenyi Biotech, 
Auburn, CA) was prepared by washing the column with 3 mL of PBS supplemented with 
2 mM EDTA and 0.05% BSA.  60 μL of ICAM-Fc (R&D Systems, Minneapolis, MN) at 
200 μg/mL was added to 200 μL of Protein G magnetic beads to saturate the beads 
with ICAM; the ICAM-Protein G beads were incubated at 4°C for 45 minutes.   The 
ICAM-Protein G beads were applied to the LS column and washed three times with 5 
mL of PBS with 1 mM MgCl2 and 0.1% BSA to remove an unbound ICAM-Fc.  The 
complexed ICAM-Protein G beads were eluted with 500 μL of buffer and 450 μL of the 
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ICAM-Protein G beads were then applied to  108 yeast.  The library and complexed 
ICAM-Protein G beads were incubated for 1 hour at 4°C.  Meanwhile, a new LS column 
was prepared as previously described.   The yeast/bead mixture was added to the 
column, washed with buffer as before, and eluted with 5 mL of PBS plus 2 mM EDTA 
and 0.05% BSA.  The eluate was then used to inoculate 245 mL of SD-CAA.  
3.2.3  Flow cytometry 
Yeast were grown and induced as previously described in section 3.2.1.  
Following overnight induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were 
transferred to microcentrifuge tubes for washing and immunofluorescent labeling.  Yeast 
were washed twice with 500 μL Labeling Buffer (137 mM NaCl, 2.7 mM KCl, 10mM 
Na2HPO4, 2mM KH2PO4, 10 mM MgCl2, and 1 mM CaCl2).  Following the washes, cells 
were incubated with mouse anti-c-myc antibody 9E10 (ascites fluid, Covance, 
Princeton, New Jersey) at a 1:100 dilution in Labeling Buffer for 45 to 60 minutes at 4°C 
along with either smMLCK peptide or a scrambled version of smMLCKp (henceforth 
referred to as „scrampep‟) at a concentration of 10 μM.   Yeast were washed once with 
500 μL of Labeling Buffer then resuspended in 30 μL for labeling with fluorescent 
secondary antibodies and precomplexed ICAM-Fc/anti-Fc AF647.  1.5 μL of ICAM-Fc 
per sample (200 μg/mL) (R&D Systems, Minneapolis,MN) was precomplexed with Alexa 
Fluor 647-conjugated goat anti-human anti-Fc secondary antibody (Jackson 
ImmunoResearch, West Grove, PA) at a ratio of 1:1.6 at 4°C for at least 60 minutes.  
Yeast were costained with precomplexed ICAM-Fc/AF647 anti-Fc, at a final ICAM-Fc 
concentration of 10 μg/mL, goat anti-mouse Alexa Fluor 488 (Invitrogen) at 1:100 and 
smMLCKp or scrampep at room temperature, protected from light for 1-2 hrs.  Following 
the secondary incubation, yeast were spun down at 10,000xg for 1 minute and 
resuspended in 1 mL of fresh Labeling Buffer.  Samples were analyzed on an Accuri C6 
flow cytometer (BD Biosciences, Ann Arbor, MI).  10,000 events were collected per 
sample and gated based on size.  Background-corrected mean AF647 fluorescence 
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(i.e., ICAM-1 binding) was normalized by background-corrected mean AF488 
fluorescence (i.e., full length protein surface expression).  Normalized mean 
fluorescence of ICAM-binding of samples incubated with smMLCKp  was divided by 
normalized mean fluorescence of ICAM-binding of samples incubated with scrampep to 















where NMFI is the normalized mean fluorescence intensity, MFI 647sample is the mean 
fluorescence intensity due to ICAM-binding by the sample protein , MFI647bkgd is the 
mean fluorescence intensity of ICAM binding by a negative control population 
expressing a disparate protein on the yeast surface, MFI 488sample is the mean 
fluorescence intensity of protein expression by the sample protein and MFI 488bkgd is 
the mean fluorescence intensity of protein expression by uninduced yeast. 
3.2.4  Library construction of circularly permutated I domain  
A short, six amino acid linker containing two BamHI restriction sites used to 
circularize the gene (GGGSG) was added by PCR and referred to as Id6L.  400 μg of 
plasmid DNA containing Id6L was digested with 2,000 units of BamHI (New England 
Biolabs Inc., Ipswich, MA) for six hours at 37°C.  The digest was stopped with 10X stop 
buffer (recipe).  Linearized Id6L  was gel purified and then ligated into circular genes 
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using T4 Ligase (NEB) overnight at 16°C.  Overnight ligations were desalted using 
Promega PCR clean-up kit (Promega, Madison, WI).  Circularized Id6L (10 μg) was 
then digested with 20 mUnits of DNaseI (NEB) for 10 minutes at room temperature in a 
total reaction volume of 300μL.  The DNase digest was stopped with 6 μL of 0.5M 
EDTA to a final concentration of 10 mM and heat inactivated at 65°C for 10 minutes.  
Following heat inactivation, digested DNA was desalted as previously described.  About 
3.5μg of digested DNA was repaired using 12 U of T4 ligase, 3U T4 polymerase and 
200μM dNTPs with 10X T4 ligase buffer in a total reaction volume of 200μL.  The DNA 
repair reaction was carried out at 12°C for 30 minutes and heat deactivated at 75°C for 
20 minutes using a thermocycler.  Each step is the circular permutation process was 
verified by gel electrophoresis.   pCT312 (~12 μg plasmid DNA) was digested with 15 
units of AfeI for at least 2 hours and heat inactivated at 65°C for 20 minutes.  Following 
heat inactivation of the AfeI enzyme, digested vector was dephosphorylated using 
Antarctic phosphatase at 37°C for 40 minutes and then heat inactivated at 65°C for 10 
minutes.  Digest, dephosphorylated pCT312 was analyzed by gel electrophoresis and 
the linearized, dephosphorylated vector was gel purified for ligation with the circular 
permuted Id6L library.  Circularly permuted Id6L library was ligated with linearized, 
dephosphorylated pCT312 at a ratio of 3:1 using T4 ligase and 5% PEG3350 with 10X 
T4 ligase buffer in a total reaction volume of 120μL overnight at 16°C.  Overnight library 
ligations were transformed into MegaX DH10B electrocompetent cells (Life 
Technologies, Carlsbad, CA) using 3 μL of ligated DNA and 20 μL cells per 
transformation.  Three transformations were pooled and recovered for 1 hour at 37°C 
prior to plating serial dilutions and library size was estimated to be 1x106  the following 
day.  Library DNA was purified and frozen for future use.  The circularly permuted library 
was transformed into yeast using the lithium acetate method.100 




3.2.5  Construction of switch library 
Random mutagenesis of the α7 helix and EF4 hand was performed using 
nucleotide analogs.  Ten cycles of error-prone PCR using 2.5 units of Taq polymerase 
and 500μM each of dPTP and 8-oxo-dGTP (TriLink Biotechnologies, San Diego, CA) 
introduced mutations into the switch gene between two ClaI restriction sites located 
within the gene.  Homologous recombination using 50-bp of homology on each side of 
the ClaI restriction sites allowed for efficient recombination of the mutagenized gene.  
Seven electroporations each containing 1 μg of vector DNA and 1.2 μg of library insert 
per 50 μL of EBY100 were pooled together and transformed yeast were allowed to 
recover in YPD (2% w/v dextrose, 2% w/v peptone, and 1% w/v yeast extract) for 1 hr at 
30°C.  The transformed yeast library was then spun down at 1,000xg for 3 minutes and 
resuspended in 10mL of SD-CAA and serial dilutions were plated.  Library size was 
estimated to be 1.4x107. 
3.2.6  Fluorescence-activated cell sorting 
The library was sorted a total of four times using alternating rounds of positive 
and negative selections to enrich for yeast that displayed improved switching behavior 
in response to the presence of the smMLCK peptide.  The first round of library sorting 
was a positive selection to enrich for a population that bound ICAM-1 with high affinity in 
the presence of 10 μM smMLCK peptide.  The second and third rounds were negative 
sorts to deplete the library of yeast that bound ICAM-1 in the presence of the scrambled 
peptide at 10 μM.  The fourth round of sorting was a positive sort to re-enrich for ICAM-
1 high affinity binders in the presence of 10 μM smMLCK peptide. Library expressing 
yeast were grown and induced as previously described.  Following overnight induction 
at 30°C for at least 20 hours, 3.5x107 cells (OD600 = 3.5) were aliquoted and 
immunostained as previously described.  Briefly, cells were washed with Labeling Buffer 
then labeled with anti-c-myc mouse monoclonal antibody, 9E10 (Developmental Studies 
Hybridoma Bank, University of Iowa) at a dilution of 1:50 for 1 hour on ice.  During the 
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primary incubation, library expressing yeast were incubated with either 10 μM smMLCK 
peptide or 100 μM scrambled smMLCK peptide.   Following the primary incubation, cells 
were washed with Labeling Buffer then labeled with precomplexed ICAM-1-Fc/anti-Fc 
AlexaFluor 647, smMLCKp at 10 μM or scrampep at 100 μM, and goat anti-mouse 
AlexaFluor 488 at a 1:100 dilution.   
3.2.7  Protein purification 
pET28b(+) (Novagen, Darmstadt, Germany) was used as the soluble protein 
expression vector.  Restriction sites, NheI and XhoI, were used to insert the gene of 
interest into the ORF of pet28b(+) allowing for proteins to be expressed with a N-
terminal His6 tag and a C-terminal c-myc tag to allow for diagnostic determination of full 
length protein. E. coli BL21(DE3) were transformed by electroporation using 1 μL of 
plasmid DNA per 50 μL of BL21(DE3) cells with plasmids containing genes encoding for 
either high-affinity I domain mutant F265S or fusion, switch proteins.  Overnight BL21 
cultures were diluted 1:50 into fresh LB-Kan (50 μg/mL) media and induced with 1M 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1mM at an 
OD600 between 0.4 and 0.6.  Cells were allowed to continue growing following induction 
for another 3-6 hours.  Cells were harvested by centrifugation at 5,000xg for 10 minutes 
and frozen cell pellets were stored at -20°C until the protein was extracted.  Cell pellets 
were thawed on ice and then resuspended in 10 mL/g cells B-PER (Thermo Scientific, 
Rockford, IL) and 5 μL/g cell pellet of DNaseI (NEB).   Cell suspensions were 
homogenized with a needle and syringe for about 5 minutes and allowed to incubate at 
room temperature for 15 minutes with mild shaking.  Soluble protein (fusion protein 
switches) was collected in the soluble fraction following centrifugation at 15,000xg for 15 
minutes.  High affinity I domain is found in inclusion bodies and had to be further 
purified from inclusion bodies.  The pellet containing inclusion bodies was resuspended 
in 5 mL B-PER and 4 μL Lysozyme (50 mg/mL) and homogenized, incubated at room 
temperature and centrifuged as with the separation of the soluble fraction previously 
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described.  This process was repeated twice more to isolate inclusion bodies and then 
resuspended in Buffer A (50 mM phosphate, 8 M urea, pH 7.5) and boiled for 1 hr.  
Protein refolding was accomplished using an on-bead method.101  Briefly, solubilized 
H.A. Id was added to prepared TALON cobalt resin (Clontech, Mountain View, CA) and 
shaken overnight at 4°C.  The slurry was then washed twice with 40 mL of refolding 
buffer (50 mM phosphate, 1 mM MgSO4, 5% (v/v) glycerol, pH 7.5) and resuspended in 
30 mL of refolding buffer and allowed to shake gently overnight at 4°C.  The 
beads/protein were collected in a column, washed twice with 5 CV of Equilibrium/Wash 
Buffer (50 mM phosphate, 300 mM NaCl, pH 7.0) and eluted with 2X 1.5CV of Elution 
Buffer (50 mM phosphate, 300 mM NaCl, 300 mM imidazole, pH 7.0).  Fractions were 
confirmed by western blotting or Coomassie staining.   His-purified proteins were further 
purified using the ÄKTApurifier with a Superdex 200 10/300 GL column (GE Healthcare 
Bio-Sciences, Pittsburgh, PA) according to the manufacturer‟s instructions to remove 
impurities that eluted from the TALON resin.  Briefly, purified proteins were dialyzed into 
SPR Buffer (20 mM Tris, 150 mM NaCl, 10 mM MgCl2, 2 mM CaCl2, 0.01% (v/v) 
Tween-20, pH 8.0) using Slide-A-Lyzer cassettes (Thermo) following the manufacturer‟s 
instructions.  Briefly, 3 mL of eluted protein was added to the cassette, dialyzed in 
2X500 mL of SPR buffer at room temperature for 2 h each.  Buffer was then replaced 
with 500 mL of fresh SPR buffer and dialyzed overnight at 4°C with gentle stirring.  
Dialyzed protein was then removed from the cassette and stored at 4°C until purification 
on the FPLC.  Prior to loading protein on the FPLC, it was concentrated using Amicon 
Ultra centrifugal filter units (Millipore, Billerica, MA).  500 μL of concentrated protein was 
loaded onto a Superdex 200 10/300GL and eluted with 1.5 column volumes of buffer.  
Fractions were collected, analyzed by SDS-PAGE and saved for surface plasmon 
resonance experiments. 




3.2.8  Surface Plasmon Resonance 
Protein switch activity was analyzed using surface plasmon resonance.  ICAM-Fc 
was immobilized at a level of 1220 RU (response units) on a CM5 sensor chip using the 
amine coupling kit (BIAcore, Piscataway, NJ).  Analytes were flowed over the 
immobilized ICAM-Fc at a flow rate of 10 μL/min, 25°C in SPR buffer plus either 
scrampep or smMLCKp at 10 μM.   Analyte was injected for 240 sec at the following 
concentrations: 200 μM, 100 μM, 20 μM, 10 μM, 2 μM, 1 μM, 200 nM, 100 nM and 2 
nM. Analyte was dissociated using 20 mM Tris (pH 8), 300 mM NaCl and 20 mM EDTA.   
An adjacent flow cell was left empty and blocked and used as a control to subtract bulk 
effects.   Kinetic analyses were performed using Scrubber2 after subtracting bulk 
change and nonspecific binding. 
3.3  Results 
3.3.1  Circular Permutation 
Circular permutation is an efficient method for identifying sites amenable to 
domain insertion.   This approach has been successfully applied to create a number of 
different proteins whose function is allosterically regulated following domain insertion.16; 
19; 97  Following the creation of the circularly permuted I domain library and 
transformation into E. coli, seventeen colonies were randomly selected and sequenced 
to verify that the library contained full-length, circularly permuted I domain. Out of the 17 
sequences, 2 (11.8%) didn‟t contain the I domain gene (i.e., they were re-ligated 
vector), 9 (52.9%) contained full-length, circularly permuted I domain sequences, and 6 
(35.3%) contained extremely truncated (<40% of total sequence) versions of the gene.  
Since the I domain gene with the GGGSG linker is 570 bp the library needs to contain at 
least 1615 clones to theoretically sample each DNase I cut site within the gene 
assuming that 35.3% of genes remain full-length following the circular permutation.  The 
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circularly permuted I domain library was transformed into yeast and contained 106 
transformants, thereby ensuring that the entire library was adequately sampled.  
Clones were initially screened by two rounds of magnetic-activated cell sorting 
(MACs) to deplete the library of nonfunctional clones and enrich for binders (Figure 3.3).  
The first round of MACS resulted in roughly two-fold enrichment for ICAM binders.  
Following the second round of MACS the library was enriched 10-fold over the starting 
library for ICAM binders (Figure 3.3). This enriched library was then recovered by 
growing in SD-CAA media and sorted by FACS.  Following one round of fluorescence-
activated sorting, a population was enriched 17-fold for permutants that retained the 
ability to bind ICAM.  Twenty clones were then analyzed for their specific ability to bind 
ICAM and to determine their new sequence.  Interestingly, in all of the permutants that 
retain ICAM binding, only changes to their C-terminal allosteric region including the β6-
α7 loop and the α7 helix were tolerated.   Previous studies have shown that the 
allosteric region, residues Y257 to E310, of LFA-1 I domain is critical for relaying the 
conformational changes of the whole integrin to the active site in order to bind ICAM-1 
with high affinity.28; 93  The circular permutation results indicating that this region of the 
protein is the most tolerant to changes in its structure, coupled with previous studies 
identifying the importance of this region for ICAM-1 binding, led to the design of primers 
to focus random mutagenesis in this region.  
3.3.2  Directed evolution for improved switches 
A library of approximately 1.5 x 107 EF3-I domain-EF4 switch mutants was 
created using error prone PCR with 500 μM nucleotide analogs.  Four rounds of 
fluorescent activated cell sorting (FACS) were conducted to try and isolate a population 
of switch proteins whose affinity for ICAM-1 was allosterically regulated by the binding 
of an agonist peptide, smMLCK.  The naïve library was phenotypically similar to the 




Figure 3.3   MACS enrichment of functional circular permuted I domain library.  A)  
Naïve library of circular permuted I domain.  B)  Following a single round of MACS, the 
library was enriched by roughly two-fold over the naïve library.  C) A second round of 







absence or presence of scrambled peptide, respectively, while 12.9% of the original I 
domain-calmodulin fusion, referred to  henceforth as wild-type switch, bound ICAM-1 in 
the absence of peptide (Figure 3.4 A and B).  In the presence of smMLCK peptide, 
22.9% of the naïve library bound ICAM-1, similar to the wild-type switch with 23.8% 
bound ICAM-1 with smMLCK present.  The first round of sorting conducted with 10 μM 
smMLCK peptide was used to isolate populations that bound ICAM-1 with increased 
affinity.  Following the first sort, 42.8% of the library was able to bind ICAM-1 in the 
presence of the antagonist peptide (i.e., scrambled peptide) while 47.5% of the library 
population bound ICAM in the presence of the agonist peptide (i.e., smMLCKp) (Figure 
3.4C). The next two rounds of sorting were considered to be negative sorts where 
library expressing yeast that bound ICAM in the presence of 10 μM scrambled peptide 
were excluded and only library expressing yeast that didn‟t bind ICAM in the presence 
of the scrambled peptide were collected.    Following these two negative sorts, the 
library was depleted 30-fold of proteins that bound ICAM in the presence of scrambled 
peptide resulting in a phenotypic change in the library population resembling a true off-
state (Figure 3.4E).  A final positive sort for ICAM binders in the presence of smMLCK 
was conducted to enrich the library population that, as a whole, looked to bind ICAM 
only in the presence of smMLCK.  The final sort resulted in a library population that had 
a near 3-fold increase in ICAM binding in the presence of smMLCK compared to ICAM 
binding in the presence of scrambled peptide (Figure 3.4F).   
Following the final round of FACS, yeast were plated and a total of 50 mutants 
were analyzed for switch activity.  The majority of clones showed improvements in 
switch activity with some mutants displaying as much as a 20-fold increase in ICAM-1 
binding in the presence of peptide (Figure 3.5).  A few clones demonstrated decreased 
ICAM binding in the presence of smMLCKpeptide.  Eight of the top clones and four of 
the clones that had decreased switch activity were sequenced to identify mutations that 
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Figure 3.4  Directed evolution of EF3-I domain-EF4 switch via FACS.  Flow cytometry 
plots showing both protein surface expression and ICAM-1 binding in the presence of 
either smMLCKp (agonist) or the scrambled version of smMLCKP (scrampep, 
antagonist).  Surface expression is displayed on the vertical axis in mean fluorescence 
intensity (MFI) and cells above the horizontal gate can be considered to be expressing 
full length switch constructs.  ICAM-1 binding is displayed on the horizontal axis in MFI 
and cells to the left of the vertical gate can be considered to have proteins binding 
ICAM-1. A) Wild-type switch B) Naïve library (i.e., library expressing yeast prior to 
sorting) C) Switch library following the first sort with smMLKCp D) Library following a 
negative sort in the presence of scrampep E) Library following a second negative sort in 
the presence of scrampep F) Library following the last round of sorting; a positive sort in 


















   
 








Figure 3.5  Analysis of individual clones following four rounds of directed evolution for 
improved switched.  Fifty clones were analyzed for their switching ability relative to the 
wild-type switch.  Fold change is calculated as discussed in the materials and methods 
section.   The top 9 clones were sequenced to identify mutations that improved switch 
activity in the presence of smMLCKp and three of the lowest switch activity clones were 
also sequenced to identify mutations that improved the “off-state” of the switch in the 





Sequenced for improved switch activity 
Sequenced for good “off-state” 
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both decreased ICAM binding in the presence of the scrambled peptide and increased 
ICAM binding in the presence of smMLCKp.   
3.3.3  Mutations affecting switch activity 
Seventeen unique mutations were found in the twelve mutants that were 
sequenced (Table 3.1). Three mutations (L289R, E293A, and Y307D) were found in 
multiple mutants, and all were located in either the β6-α7 loop or the α7 helix of the 
allosteric region of I domain.  Three mutations (I318S, M337V, and K341E) were 
located in the EF4 domain of calmodulin.  The double mutant, Leu-289-Arg and Tyr-
307-Asp, was found in three of the seventeen mutants sequenced. Tyr-307 was also 
mutated to a serine.    The frequency in which position 307 was mutated highlighted the 
need to explore the role of this position in affecting switch activity. A fourth double 
mutant, clone 21, which demonstrated decreased switch activity compared to the wild-
type switch contained the mutations L289R and I231L.  Given the conservative nature 
of the isoleucine to leucine mutation, it was hypothesized that L289R is responsible for 
locking the switch in a low affinity state. A series of sixteen single, double, triple and 
quadruple mutants were created from the mutations found through directed evolution to 
try and identify a synergistic set of mutations to further increase switch activity (Table 
3.2).   
The only single mutant, M8, contained the Leu-289-Arg mutation thought to lock 
the switch in a low affinity state.  As predicted, M8 saw a decrease in switch activity 
relative to wild type switch and lacked the ability to bind ICAM-1 in the presence of 
smMLCK peptide (Table 3.2 and Figure 3.6). This mutation was included in the other 15 
mutants to improve the off-state of the switch in the presence of scrambled peptide.  
Mutants M5, M6, and M7 all contained the EF4 mutation I318S and resulted in 
decreased switch activity.  Double mutants, M2 and M3, differing in which EF4 residue 











Fold Change in ICAM 
Binding 
Wt Wild type 2 
1 K263R, D290A, Y307D, K341E 8.5 
2 Y307S 9 
14 M337V 12 
20 L289R, Y307D 7 
21 L289R, I231L 0.5 
22 I258L, E293A 5 
29 L289R, Y307D 5 
33 V286G 2 
34 T273P 5.5 
39 E241V, F277C, K280N, I318S 0.5 
41 L289R, Y307D 10 
44 K252Q, E293A 23 
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Clone Mutations Fold Change in ICAM Binding 
wt Wild type 4.4 ± 0.8 
M1 L289R, I318S 0.3 ± 0.2 
M2 L289R, M337V 11.2 ± 2.8 
M3 L289R, K341E 19.9 ± 16.8 
M4 L289R, M337V, K341E 8.1 ± 2.5 
M5 L289R, I318S, M337V 4.3 ± 2.3 
M6 L289R, I318S, K341E 1.9 ± 1.0 
M7 L289R, I318S, M337V, K341E 3.6 ± 2.4 
M8 L289R 6.8 ± 4.0 
M9 L289R, Y307D 11.2 ± 3.2 
M10 L289R, Y307S 10.3 ± 5.7 
M11 L289R, Y307D, M337V 2.0 ± 1.0 
M12 L289R, Y307S, M337V 94.3 ± 28.7 
M13 L289R, Y307D, K341E 31.1 ± 12.9 
M14 L289R, Y307S, K341E 33.4 ± 11.6 
M15 L289R, Y307D, M337V, K341E 68.0 ± 30.7 










switch activities indicating that M337V is likely more beneficial than K341E is to 
improved switching.  The effect of these two mutations is also seen when comparing 
M12 and M14.  Comparing M11 to M12, M13 to M14 and M15 to M16, it appears that 
Y307S is more beneficial than Y307D to improving switch activity. Two of the three 
mutations of the EF4 domain, M337V and K341E, likely increase the specificity of the 
EF hands for smMLCKp in relation to scrambled peptide.  The third mutation, I318S, is 
thought to disrupt the hydrophobic pocket created by the two EF hands in which Trp-
799 of smMLCK peptide is buried.  This disruption of the hydrophobic pocket by 
substitution with a polar residue diminishes peptide binding and therefore switch activity. 
3.3.4     Effect of peptide concentration on switch activity 
The effect of peptide on switch activity was tested by incubating the wild-type 
switch and one of the top performing switches, M12, with differing concentrations of 
smMLCK and scrambled peptide.  Peptide concentrations ranging between 200 nM and 
200 μM were tested.  At concentrations of smMLCK peptide above 100 μM the amount 
of ICAM-1 bound by both switches increases significantly and both wild-type and M12 
switches bind ICAM-1 with similar affinities in the presence of 200 μM smMCK peptide 
(Figure 3.7).  However, a noticeable difference in ICAM-1 affinity is seen between the 
two switches in the presence of the scrambled peptide.  Scrambled peptide at 200 μM 
causes about at 40% increase in ICAM-1 binding with the wild-type switch compared to 
switch M12 (comparing ICAM-1 binding fluorescence intensity at 200 μM with 
scrambled peptide).   Similarly, the fluorescence intensity associated with ICAM-1 
binding in the presence of the scrambled peptide is consistently lower across all peptide 
concentrations with the M12 switch compared to the wild-type switch.  The lowered 







Figure 3.7  Effect of peptide concentration on switch activity.  Wild-type (A) and M12 (B) 
switches were incubated with peptide at final concentrations between 200 nM and 200 
μM and ICAM-1 binding was measured by flow cytometry.   Mean fluorescence intensity 
from ICAM-1 binding was plotted against peptide concentration and curves were fit 
using Prism. 
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3.3.5   Soluble protein analysis 
To accurately determine binding affinities for the engineered switches, as well as 
rule out any artifacts due to the surface display construct, soluble switches were 
produced for binding kinetics analysis using surface plasmon resonance.   ICAM-Fc was 
immobilized on the sensor surface of a CM5  chip and switches in the presence of 10 
μM smMLCK or scrambled peptide were flowed over the senor surface and ICAM-1 
binding was measured in real time.  Affinity measurements for a first generation switch, 
Switch 9, was found to be 132 μM in the presence of smMLCK peptide and 550 μM in 
the presence of scrambled peptide (Table 3.3 and Figure A10.1).  This 4.2-fold change in 
ICAM binding in the presence of the effector peptide, smMLCK, is consistent with what 
has been observed by flow cytometry with this switch.  Additionally, by inspection of 
ICAM binding by flow cytometry reveals that this switch likely has low to „intermediate‟ 
ICAM-1 affinity based on comparison between high affinity and low affinity I domain 
controls.  Additionally, comparison of the kon and koff for this switch are consistent with 
previously measured association and dissociation rate constants for different I domain 
mutants regarded as having intermediate ICAM affinities.93  I domain mutants from this 
study had reported kon between 133 x 10
3 and 3.4 x103 M-1 s-1, koff between 0.43 and 1.2 
s-1, and KD between 3.0 and 450 μM for intermediate to low-intermediate affinity I 
domain mutants.93 
3.4  Discussion 
Previous work has developed an allosteric switch by fusing the EF3 and EF4 
hands of calmodulin to the N- and C-termini of I domain, respectively, resulting in a 
chimeric fusion protein with a modest two-fold increase in ICAM-1 binding in presence 
of smMLCK peptide .89  This work sought to improve the switch activity of the initial 
switch construct, herein referred to as the wild-type switch, by improving the off-state of 
the fusion protein through directed evolution (i.e., minimize ICAM-1 binding in the 
absence of peptide/presence of scrambled peptide) while retaining ICAM-1 binding at 
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Switch Peptide kon (M
-1·s-1 x 10-3) koff (s
-1) KD (μM) 
Fold 
Change 
SW 9 scrambled 0.96 ± 0.5 0.48 ± 0.05 550 ± 220 
 
SW 9 smMLCK 2.7 ± 0.8 0.34 ± 0.05 132 ± 15 4.2 
      
SW 1 scrambled 1.0 0.57 570 
 
SW 1 smMLCK 1.2 0.22  190 3.0 
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near wild-type levels in the presence of smMLCKpeptide.  Previous studies have shown 
the power of combining circular permutation and domain insertion to create protein 
fusions that effectively couple β-lactamase activity to the presence of maltose.97  Our 
first approach to improving the switch activity of the EF3-I domain-EF4 construct was to 
create and screen a library of circularly permuted I domains to identify a non-obvious 
site within the I domain structure that would be amenable for domain insertion.  
Interestingly, only new termini in the allosteric region of the I domain were tolerated.  
This finding was significant in two ways.  First, it reiterated the importance of this part of 
the I domain in controlling ICAM-1 binding through allosteric rearrangements in the I 
domain, reaffirming previous findings.28; 93   Second, it provided a site to focus 
mutagenesis to try and introduce mutations that could improve the switch activity of an 
EF3-I domain-EF4 fusion.  As the β6-α7 loop is displaced by the downward movement 
of the α7 helix, three residues, Leu-295, Phe-292 and Leu-289, located along the β6-α7 
loop occupy a hydrophobic pocket in succession as the I domain goes from a closed, to 
an intermediate, to an open conformation, respectively.  Additionally, the movement of 
the α7 helix and the β6-α7 loop disrupts the hydrophobic core of the protein along with a 
network of hydrogen bonds within the central β-sheet structure of the I domain, this 
disruption causes rearrangements of loops containing MIDAS coordinating residues 
bringing the MIDAS residues into a high affinity conformation and completing 
transmission of the allosteric signal from the allosteric region to the ICAM-1 binding site 
of the MIDAS.28; 93; 102  Prior to performing focused random mutagenesis on the 
allosteric region of the protein, a fusion was constructed where the α7 helix of the I 
domain was replaced by a short GGG linker connecting the EF4 hand directly to the 
allosteric region of the I domain to hopefully cause a greater disruption of the allosteric 
region upon peptide binding.  However, this construct resulted in negligible 
improvement in switch activity necessitating the need for focused random mutagenesis 
(data not shown). 
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The mutation, Leu-289-Arg, which appeared in four of the clones, three of which had the 
identical double mutation of Leu-289-Arg and Tyr-307-Asp, is critical for improved 
switching.  Upon examination of the low affinity crystal structure of the αL I domain Arg-
289 likely forms a salt bridge with residue Glu-301 (Error! Reference source not 
found.).  A salt bridge prevents the transition from a low affinity conformation to a high 
affinity conformation, thus locking the α7 helix in place and preventing the I domain from 
binding ICAM-1.  Clone M8, which contained the single mutation L289R did indeed 
show negligible ICAM-1 binding confirming that Leu-289-Arg does keep the I domain in 
a low affinity conformation. 
Two amino acids that are beneficial to improved switch activity, aspartic acid and 
serine, were found in place of the wild-type tyrosine at position 307.  Both aspartic acid 
and serine are much smaller than tyrosine and position 307 is the last I domain residue 
prior to a short linker and the EF4 hand on the C-terminal end of the fusion.  The 
smaller side chains of aspartate and serine may provide the EF4 hand more flexibility 
allowing the EF4 to adopt a large range of conformations to improve smMLCK peptide 
binding.   Furthermore, it appears that shorter is better.  Comparing mutants where the 
only difference is whether Tyr-307 has been changed to an aspartate or serine, mutants 
with the shorter serine side chain mutation have marked improvement in switch activity.   
The two mutations associated with the EF4 hand that improve the switch activity 
of the fusion are M337V and K341E.  Each of these mutations probably contributes to a 
number of small beneficial interactions and cumulatively these interactions increase the 
affinity of the EF4 hand for the effector peptide.  The smaller side chain of valine likely 
allows for tighter packing of Trp-799 of the peptide into the hydrophobic pocket of the 
EF4 hand strengthening the hydrophobic interaction between the peptide and EF4.  
Similar electrostatic interactions between the mutated Lys-341-Glu and the positively 




Figure 3.8  L289R mutation creates an ion pair with Glu-301.  The Leu-289-Arg 
mutation was modeled into the low affinity I domain crystal structure (PDB 1LFA) using 
Swiss-PdbViewer (http://www.expasy.org/spdbv/)103 and the rotamer with the lowest 
score was selected.  The L289R mutation was then analyzed in PyMol and determined 
to make an ion pair with Glu-301 of the α7 helix.  Amino acid side chains are shown as 
ball and stick with Arg-289 in purple and Glu-301 in orange.   
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peptide.  The N-terminus of smMLCK peptide is littered with positively charged residues 
providing ample opportunity for attractive charge-charge interactions to occur between 
the positively charged N-terminus of the peptide and the negatively charged glutamic 
acid.  The magnitudes these mutations have on improved switch activity are likely very 
similar as neither M337V or K341E clearly outperforms the other mutation.  Thus, the 
effect of either of these mutations in combination with Y307S and L289R improve the 
switch activity of the protein.  
Taken together, mutant M12, which contains L289R, Y307S and M337V 
mutations, was consistently the best performing switch.  The effects of the different 
mutations seem to indicate that L289R provides a stabilizing force maintaining the I 
domain in a closed conformation.  Presumably, binding of the EF3 and EF4 hands to 
smMLCK peptide sufficiently disrupts the salt bridge between L289R and E301 allowing 
the I domain to relax into a higher affinity conformation.  The overall effect is that, in the 
presence of scrambled peptide, the EF3 and EF4 hands do not associate strongly 
enough to disrupt the Arg-289–Glu-301 salt bridge providing a true, low affinity state for 
the switch.  In the presence of smMLCK peptide, the EF3 and EF4 hands are able to 
associate strongly enough to disrupt the salt bridge and allow the switch to adopt a 
higher affinity conformation. 
We have demonstrated the ability to use directed evolution to improve the switch-
like functionality of a fusion between the LFA-1 I domain and the EF3 and EF4 hands of 
calmodulin.  Previous work had developed this fusion as the first example of a protein 
switch where the controlled output function was adhesion.  The use of circular 
permutation allowed for the identification of a key structural region of the I domain, the 
allosteric region, providing some rational design guidance in subsequent directed 
evolution work.  Through focused mutagenesis on the switch-allostery region of the 
protein a complementary set of mutations both in the allosteric region of the I domain 
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and the EF4 hand of calmodulin contribute to a near 20-fold improvement over the 
original, fusion construct.  Particular detail was paid to identifying mutations that 
provided the switch an improved „off-state‟, a key in engineering any protein switch, and 
identification of the L289R mutation was critical to improving the off-state of the protein 
and providing an improved dynamic range of switch activity over the original switch.  
The ability to use directed evolution to identify mutations to rapidly improve desired 
functionality of any protein, as well as to probe the structure-function relationship and 
provide guidance for protein engineering, further illustrates the power of this approach. 
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Chapter 4 :  Directed evolution for altered peptide specificity 
4.1  Introduction 
Protein engineering has evolved from trying to better understand enzymes to a 
field focused on not only gaining insight into biological processes but also developing 
proteins for industrial and therapeutic applications.104; 105   Protein allostery, the 
reversible conformational change of a protein by regulation of an effector molecule at a 
site distinct from the active site of the protein, has been a major theme in understanding 
gene regulation, metabolic pathways, and protein structure and function over the last 50 
years. 10; 106; 107  In fact, a number of current drugs, such as valium, exploit allosteric 
perturbations, thereby „locking-in‟ a specific conformation and providing a therapeutic 
effect to the cell.108  Allosteric drugs have the ability to modulate protein activity without 
completely eliminating it, can be used in combination with drugs that target other sites to 
provide an increased, beneficial effect, and tend to be highly specific for their binding 
site.109   Specifically, drug discovery research efforts have demonstrated that G-protein-
coupled receptors (GPCRs) can be positively and negatively modulated by synthetic 
ligands.110; 111  Additionally, the ability to provide requisite effector molecules for an 
allosteric protein to function provides another layer of specificity that could be 
advantageous in a drug delivery or molecular imaging capacity. 
Our lab has previously demonstrated the first example of a chimeric, adhesive 
switch that increases affinity in the presence of an activating peptide.89  The I domain, 
located at the membrane distal end of the α subunit of the integrin LFA-1, contains the 
entire ligand binding site of the macromolecule.  Through inside-out signaling the 
integrin is activated and begins to refold from its low-affinity, bent conformation into an 
extended conformation resulting in the axially downward displacement of the C-terminal, 
α7 helix  of the I domain by about 10 Å.  The downward movement of the α7 helix of the 
I domain acts as a pulley causing a rearrangement of the metal ion-dependent adhesion 
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site (MIDAS) drastically altering the affinity for the ligand, ICAM-1.9; 11; 92; 95  The I 
domain served as an ideal candidate for a protein switch as the natural allosteric 
movement of the protein, typically induced by the surrounding domains of the LFA-1 
integrin, could be induced by a second protein fused to the I domain.  This was 
accomplished by fusion of the EF3 and EF4 hands of calmodulin to the N- and C-termini 
of the I domain, respectively.   
Calmodulin (CaM) is an ubiquitous Ca2+ sensing protein that binds a number of 
different target proteins, including smooth muscle myosin light chain kinase (smMLCK).  
The TR2C domain of CaM, composed of EF3 and EF4 hands, binds smMLCK peptide 
with an affinity of 80 nM.98 The EF3 and EF4 hands have also demonstrated the ability 
to recombine in the presence of a 20 residue peptide of smMLCK in solution.98  The 
binding of smMLCK by CaM, along with a number of other peptides, has been well 
characterized and classified based on their sequence motif.112; 113 The smMLCK peptide 
used in these studies resides in the 1-14 class of CaM target proteins and more 
specifically the subclass, basic 1-8-14.112  Target peptide classes are defined by the 
location of consensus hydrophobic residues.  In the basic 1-8-14 subclass, three basic 
residues precede a consensus hydrophobic residue.  This is followed by another 
hydrophobic residue seven amino acids later, followed by a basic residue five amino 
acids later which is immediately followed by the final consensus hydrophobic amino 
acid.  In Chapter 3, a scrambled version of smMLCK was used as a negative control.   
Importantly, the scrambled version of smMLCK contained significantly different residues 
at the key locations within the basic 1-8-14 motif (Table 4.1).   The differences in amino 
acid composition at these locations between the two peptides allowed for the binding of 
smMLCK and the inability to bind scrambled peptide, and it is these differences that will 
be exploited to alter the peptide specificity of our switches.
85 
 
Table 4.1  Peptide sequences 
Peptide Name Sequence* 
smMLCK ARRKWQKTGHAVRAIGRLSS 




*  Basic 1-8-14 sequence ( β β β φ - - - - - - φ - - - - β φ - - -), 
where β represents a basic residue and φ represents a hydrophobic residue.  The key 





 The initial fusion construct, referred to as wild-type switch, had a near 2-fold 
change in ICAM-1 binding in the presence of the smMLCK peptide compared to ICAM-1 
binding in the absence of peptide.89  The protein switch was then further engineered 
using directed evolution in Chapter 3 to improve the switch activity of the protein 20-fold 
over the original switch.   To make an adhesive switch of this nature more viable for 
eventual applications the ability to alter the specificity of the effector peptide is critical.  
To this end, we show that it is possible via directed evolution to alter the peptide 
specificity of a previously engineered I domain-EF hands switch such that the switch 
now responds to peptide that had previously served as a negative control. 
Demonstrating the ability to manipulate a complicated protein switch to respond to 
different effector peptides makes it amenable for a wide array of applications and 
environments where the specificity of the effector peptide could be tailored to a specific 
application.   
4.2  Materials and Methods 
4.2.1  Yeast strains and plasmids 
S. cerevisiae EBY100 (MATa AGA1::GAL1-AGA1::URA3 ura3-52 trp1 leu2Δ1 
his3Δ200 pep4::HIS3 prb1_1.6R can1 GAL) cells were transformed with pCT302-
derived vectors allowing for selection under Trp- and Ura- conditions and surface 
expression of proteins under the galactose inducible GAL1,10 promoter.99 pCT302 was 
used as the expression vector and  fusion constructs were cloned in using NheI and 
BamHI restriction sites.  Use of NheI and BamHI restriction sites allows two epitope tags 
(HA or c-myc) on either side of the gene of interested to be expressed in the 
ORF.    Yeast were grown in the semi-defined media SD-CAA (20g/L dextrose, 6.7 g/L 
yeast nitrogen base without amino acids, 5.4 g/L Na2HPO4, 9.7 g/L NaH2PO4·H2O, and 
5 g/L CAA) at 30°C overnight.  The following day, expression was induced by 
subculturing at an OD600 of 1 and grown overnight in SGR-CAA (same as SD-CAA 
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except 2% (w/v) dextrose is replaced with 2% (w/v) galactose and 2% (w/v) D-
Raffinose).   
4.2.2  Flow cytometry 
Yeast were grown and induced as previously described in section 3.2.1.  
Following overnight induction in SGR-CAA at 30°C, 3x106 cells (OD600 of 0.3) were 
transferred to microcentrifuge tubes for washing and immunofluorescent labeling.  Yeast 
were washed twice with 500 μL Labeling Buffer (137 mM NaCl, 2.7 mM KCl, 10mM 
Na2HPO4, 2mM KH2PO4, 10 mM MgCl2, and 1 mM CaCl2).  Following the washes, cells 
were incubated with mouse anti-c-myc antibody 9E10 (ascites fluid, Covance, 
Princeton, New Jersey) at a 1:100 dilution in Labeling Buffer for 45 to 60 minutes at 4°C 
along with either smMLCK peptide or a scrambled version of smMLCKp (henceforth 
referred to as „scrampep‟) at a concentration of 10 μM.   Yeast were washed once with 
500 μL of Labeling Buffer then resuspended in 30 μL for labeling with fluorescent 
secondary antibodies and precomplexed ICAM-Fc/anti-Fc AF647.  1.5 μL of ICAM-Fc 
per sample (200 μg/mL) (R&D Systems, Minneapolis,MN) was precomplexed with Alexa 
Fluor 647-conjugated goat anti-human anti-Fc secondary antibody (Jackson 
ImmunoResearch, West Grove, PA) at a ratio of 1:1.6 at 4°C for at least 60 minutes.  
Yeast were costained with precomplexed ICAM-Fc/AF647 anti-Fc, at a final ICAM-Fc 
concentration of 10 μg/mL, goat anti-mouse Alexa Fluor 488 (Invitrogen) at 1:100 and 
smMLCKp or scrampep at room temperature, protected from light for 1-2 hrs.  Following 
the secondary incubation, yeast were spun down at 10,000xg for 1 minute and 
resuspended in 1 mL of fresh Labeling Buffer.  Samples were analyzed on an Accuri C6 
flow cytometer (BD Biosciences, Ann Arbor, MI).  10,000 events were collected per 
sample and gated based on size.  Background-corrected mean AF647 fluorescence 
(i.e., ICAM-1 binding) was normalized by background-corrected mean AF488 
fluorescence (i.e., full length protein surface expression).  Normalized mean 
fluorescence of ICAM-binding of samples incubated with smMLCKp  was divided by 
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normalized mean fluorescence of ICAM-binding of samples incubated with scrampep to 















where NMFI is the normalized mean fluorescence intensity, MFI 647sample is the mean 
fluorescence intensity due to ICAM-binding by the sample protein , MFI647bkgd is the 
mean fluorescence intensity of ICAM binding by a negative control population 
expressing a disparate protein on the yeast surface, MFI 488sample is the mean 
fluorescence intensity of protein expression by the sample protein and MFI 488bkgd is 
the mean fluorescence intensity of protein expression by uninduced yeast. 
4.2.3  Peptide specificity library construction 
Saturation mutagenesis via overlap extension PCR was used to change seven 
residues thought to participate in the binding of smMLCK peptide.  NNK codons were 
used to randomize the seven amino acids in the EF3 and EF4 hands.  Four primers 
were used to create the library (Table 4.2).  Briefly, the primers encoded for mutations 
at key residues using NNK codons and both primers in each direction contained 20 bp 
of homology with each other to ensure efficient overlap of the gene PCR products.  The 
„outside‟ primers also contained 50 bp of homology to the pCT302 vector for 
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*  Homologous sequences between both „inside‟ primers and both „outside‟ primers are underlined. 
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homologous recombination in yeast.  The „inside‟ primers were used to carry out the 
initial PCR reaction using 50 ng of the M12 switch gene as the template DNA with 2.5 
units of Taq DNA polymerase (NEB, Ipswich, MA), primers at a final concentration of 
200 nM each, 5 μL of 10X Standard Taq Reaction Buffer (NEB), 1 μL of dNTPs (10 
mM), 2 μL of MgCl2 (25 mM), and dH2O to a final reaction volume of 50 μL.  The PCR 
reaction had the following steps: 1) 68°C for 2 min  2) 95°C for 30 seconds 3) 68°C for 
30 seconds 4) 68°C for 50 seconds, 5) repeated steps 2-4 30 times 6) 68°C for 5 
minutes 7) hold at 4°C.  The PCR product was analyzed on a 1% agarose gel and 
purified using the Wizard SV gel and PCR clean-up system (Promega, Madison, WI) 
following the manufacturer‟s instructions.   The purified PCR product was then used as 
the DNA template for the second PCR and was performed as just described with the 
only exception being the total volume of the reaction was increased to 1 mL.  The 
second, full length PCR product was again analyzed and purified as described.  Purified 
DNA was then concentrated using Pellet Paint Co-precipitant (EMD Millipore, Billerica, 
MA) following the manufacturer‟s instructions.  Homologous recombination using 50-bp 
of homology on each side of the NheI and BamHI restriction sites allowed for efficient 
recombination of the library into the linearized pCT302 expression vector.  Seven 
electroporations, each with 3 μg of library DNA and 125 ng of linearized vector, were 
pooled together and transformed yeast were allowed to recover in YPD (2% w/v 
dextrose, 2% w/v peptone, and 1% w/v yeast extract) for 1 hr at 30°C.  The transformed 
yeast library was then centrifuged at 1,000xg for 3 minutes and resuspended in 10mL of 
SD-CAA and serial dilutions were plated.  Following three days growth at 30°C colonies 
were counted on the serial dilution plates and library size was estimated to be 2x106 
4.2.4  Fluorescence-activated cell sorting 
The library was sorted a total of four times using alternating rounds of positive 
and negative selections to enrich for yeast that displayed switching behavior in 
response to the presence of the scrambled peptide.  The first two rounds of library 
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sorting were positive selections to enrich for a population that bound ICAM-1 in the 
presence of 100 μM scrambled peptide.  The third round was a negative sort to deplete 
the library of yeast that bound ICAM-1 in the presence of smMLKC peptide at 100 
μM.  The fourth round of sorting was a positive sort to re-enrich for ICAM-1 binders in 
the presence of 100 μM scrambled peptide. Library expressing yeast were grown and 
induced as previously described.  Following overnight induction at 30°C for at least 20 
hours, 3.5x107 cells (OD600 = 3.5) were aliquoted and immunostained as previously 
described.  Briefly, cells were washed with Labeling Buffer then labeled with anti-c-myc 
mouse monoclonal antibody, 9E10 (Developmental Studies Hybridoma Bank, University 
of Iowa) at a dilution of 1:50 for 1 hour on ice.  During the primary incubation, library 
expressing yeast were incubated with either 10 μM smMLCK peptide or 100 μM 
scrambled smMLCK peptide.   Following the primary incubation, cells were washed with 
Labeling Buffer then labeled with precomplexed ICAM-1-Fc/anti-Fc AlexaFluor 647, 
smMLCKp at 10 μM or scrampep at 100 μM, and goat anti-mouse AlexaFluor 488 at a 
1:100 dilution.   
4.3  Results and Discussion 
4.3.1  Library specificity construction 
  The key interacting residues of smMLCK peptide are Arg-797, Lys-799 and Arg-
812, which are involved in the formation of salt bridges, and Trp-800, which has its large 
hydrophobic side chain buried in a hydrophobic pocket created by the EF3 and EF4 
hands.113; 114 Multiple residues of EF3 and EF4 make contacts with the charged and 
hydrophobic residues of smMLCK providing attractive electrostatic interactions and a 
hydrophobic pocket for Trp-800CaM.  Residues Leu-105MLCK, Met-124 MLCK, Ala-128 MLCK, 
M144 MLCK all interact with Trp-800 CaM via hydrophobic interactions (Figure 4.1).  Glu-
127 MLCK is thought to make salt links with Arg-797 CaM and the α-amonium group of Ala-
796.  Met-124 MLCK also provides interactions to the side chain of Ala-796 CaM and Lys-






Figure 4.1  Key residues of the smMLCK and CaM interaction.  Key positions chosen 
for site-saturation mutagenesis were chosen based on literature112; 114 as well as 
analysis of the structural rendering of the interaction between the two proteins.  Here, 
key residues thought to be important for smMLCK (magenta) binding by calmodulin 
(PDB 1CDL) EF3 (light blue) and EF4 (dark blue) are shown as ball and stick.  Ca2+ 
bound by the EF hands are shown as black spheres.  W800 of smMLCK is buried in a 
hydrophobic pocket created by EF3 and EF4.  R812 of smMLCK forms an ion pair with 


















 EF3 forms a salt bridge with Arg-812 CaM of the peptide providing additional attractive 
forces for the binding of the smMLCK peptide to the EF hands of calmodulin.  Finally, in 
previous work using random mutagenesis to improve the switch activity of our EF-I 
domain protein switch, Lys-148 MLCK was found to be a beneficial mutation in a number 
of clones.  While Lys-148 MLCK is located at the extreme C-terminal end of the EF4 hand 
its frequency of mutation in previous experiments led to the conclusion that it likely 
provides some importance to binding of smMLCK peptide and was therefore included in 
the mutagenesis strategy presented here. 
 
The large number of interactions contributing to the binding of smMLCK by the 
EF hands due to just seven amino acids, out of 64 total residues in the binding cleft 
created by the EF hands, seemed to indicate that heavy mutagenesis of these residues 
could provide sufficient enough change to be able to switch the peptide specificity of the 
calmodulin domain.   It was reasoned that by essentially abolishing binding to the 
smMLCK peptide, a set of mutations allowing for binding to a scrambled version of 
smMLCK peptide, which had previously served as a negative control in switch 
experiments, could come to light.  Site-saturation mutagenesis using NNK degenerative 
codons and nested PCR (Table 4.2) was used to try and sample all possible amino 
acids at each of these seven positions since it was impossible to know which residues 
in the EF hands would impart new specificity.  The theoretical size of the library is 
1.3x109 which is on the cusp of yeast transformation efficiency limits.115  Factoring the 
biased representation of amino acids due to the NNK codon, the actual theoretical size 
of the library would be greater than 1.3x109 pushing the attainable size of a library 
outside the window of yeast transformation efficiency.  The estimated size of the library 
produced for screening changes in peptide specificity was calculated to be 2x106 
therefore under-sampling the entire sequence space that would like to be explored, but 
likely large enough to produce mutants with the desired characteristic of altered peptide 
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specificity.  Further directed evolution and affinity maturation could be used later to 
produce additional diversity and identify a set of mutations that improve the specificity of 
the EF hands for the scrambled peptide. 
4.3.2  Library Screening 
Similar to the sorting performed in Chapter 3 for improving the EF3-I domain-EF4 
switch, four rounds of sorting were used to screen the library for mutants with altered 
peptide specificity.  Alternating positive (in the presence of 100 μM scrambled peptide) 
or negative (in the presence of 30 μM smMLCK peptide) sorts were performed to drive 
the library population towards a phenotype that selectively bound ICAM-1 in the 
presence of scrambled peptide and didn‟t binding ICAM-1 in the presence of smMLCK 
peptide.  The naïve library showed negligibly better ICAM-1 binding in the presence of 
scrambled peptide (31.6%) than in the presence of smMLCK peptide (30.6%) (Figure 
4.2 A).   Given the shift in FL4 fluorescence (X-axis) in the non-expressing population in 
the presence of 100 μM scrambled peptide, the slight one percent increase in ICAM-1 
binding is likely due to background.  Therefore, it can be assumed that the naïve library, 
as a whole, had no specific preference for smMLCK or scrambled peptide at the outset 
of sorting.  The first round of fluorescence-activated cell sorting (FACS) resulted in a 
5.5% increase in cells that bound ICAM-1 when incubated with 100 μM scrambled 
peptide compared to cells expressing switches that bound ICAM-1 when incubated with 
10 μM smMLCK peptide (Figure 4.2 B) Following the second sort collecting switches 
that had been incubated with 100 μM scrambled peptide the library population was 
enriched by only about 2% for mutants that preferred scrambled peptide over switches 
that preferred smMLCK indicating that non-specific ICAM-1 binders had also been 
selected (Figure 4.2 C).  A third, negative sort in the presence of 30 μM smMLCK was 
used to remove library members that either bound ICAM-1 regardless of the peptide 
present or bound ICAM-1 in the presence of smMLCK.  A higher concentration of 30 μM 
of smMLCK peptide, compared to 10 μM which is the concentration routinely used in 
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Figure 4.2  Peptide specificity library at different stages of FACS.  Two color 
immunofluorescent staining of the peptide specificity library where fluorescence 
intensity on the vertical axis represents the amount of full-length surface expressed 
library protein and fluorescence intensity on the horizontal axis represents the amount 
of bound ICAM-1 in the presence of the indicated peptide.  A) The naïve library with no 
peptide, 10 μM smMLCK peptide (PEP), or 100 μM scrambled smMLCK (SCRAM).  B 
and C) The library following the first and second rounds of sorting, respectively, in the 
presence of 100 μM scrambled peptide.  D)  The library population following a third sort 
in the presence of 30 μM smMLCK peptide to deselect non-switching binders and a 




Figure 4.2  Continued 
97 
 
our switch assays, was used to increased the selective pressure for switches that 
selectively bound scrambled peptide.  A final, positive sort in the presence of 100 μM 
scrambled peptide was used to re-enrich the library population that responded to the 
presence of scrambled peptide by binding ICAM-1.  This final sort resulted in a near 5% 
increase in ICAM-1 binding when the mutant switches are incubated with scrambled 
peptide compare to smMLCK peptide (Figure 4.2 D).  Following the fourth round of 
sorting, the library was plated on SD-CAA medium and random colonies were screened 
for switch activity in the presence of scrambled peptide. 
4.3.3  Screening of individual mutants for altered specificity 
A total of 58 mutants were screened for altered peptide specificity by calculating 
the raw (no background correction) fold change in ICAM-1 binding in the presence of 
scrambled peptide over the presence of smMLCK peptide (Figure 4.3).  No background 
correction was applied in these calculations since there is minimal ICAM-1 binding in 
the presence of smMLCK peptide and subtraction of background fluorescence can 
result in negative values skewing the effectiveness of the switch.  The average fold 
change in ICAM binding in the presence of scrambled peptide versus smMLCK was 
calculated for the wild-type switch and found to be 1.48.  Since the wild-type switch has 
been shown repeatedly to respond to smMLCK peptide the expected value for switch 
activity for this switch should be less than unity (i.e., specificity for smMLCK over 
scrambled peptide).  The elevated switch activity of the wild-type protein is likely due to 
some non-specific interactions due to the 10-fold high concentration of scrambled 
peptide compared to smMLCK.  In other words, had both peptide concentrations been 
increased to 100 μM for the wild-type switch, the switch would still respond selectively to 
smMLCK as was seen in the peptide titration experiments from Chapter 3.  
Nevertheless, any switches that demonstrated a fold change greater than 1.48 were 




Figure 4.3  Screen of peptide specificity mutants for switch activity.  Fifty-eight (58) 
mutants were randomly screened at least once to determine their switch activity in 
response to scrambled peptide.  Mutants that proved promising after the initial screen 
(red) had their plasmids rescued from yeast and were retransformed into yeast to 







Eight switches, mutants 10, 26, 31, 44, 45, 48, 54, 56, 58, met or exceeded this 
threshold for switch activity and a ninth, mutant 26, looked qualitatively similar to these 
mutants and was also chosen for further examination.  Curiously, mutants 10, 26, and 
31 lacked non-expressing yeast populations (i.e., the population always located in the  
lower left quadrant of two-color flow cytometry plots due to plasmid loss) meaning that 
the gene was likely integrated into yeast genomic DNA complicating plasmid recovery.  
Plasmids were recovered for mutants that exhibited the negative population and 
phenotypes were confirmed to transfer with the plasmid. 
4.3.4  Mutations affecting peptide specificity 
Sequencing analysis revealed a total of 17 unique mutations in the EF3 and EF4 
hands of five different mutants whose plasmids were successfully recovered.  The 
majority (13/17) of these mutations were located at targeted residues (E84, L105, M124, 
E127, A128, M144, and K148) (Table 4.3).  Two mutants, 54 and 58, had identical sets 
of eight mutations; E84D, R106C, D118N, M124F, E127L, A128H, M144I and K148Y.  
Additionally, four spontaneous mutations arose through the rounds of directed evolution 
and were identified by sequencing:  E87Q, R106C, D118N and Q143R.  Three out of 
the four spontaneous mutations are charged residues indicating the importance of 
electrostatic interactions in peptide binding.  More interesting, however, is that both 
R106C and D118N always occurred together.  In the native calmodulin-smMLCK 
complex, these two side chains which are located on EF3 and EF4, respectively, form 
an ion pair with each other stabilizing the complex and presumably assist in effecting 
the switch activity of the molecule (Figure 4.4).  Taking either mutant 54 or 58 as an 
example of a set of mutations needed for altered specificity some general conclusions 
about altering specificity can be made.  Both mutants had five charged residues and 
three hydrophobic residues at the outset of the directed evolution study.  Following the 
four rounds of sorting for altered specificity, these mutants retained a negatively 
charged residue (E84D) and two hydrophobic residues (M124F and M144I) at the same 
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Table 4.3  Mutations found in altered peptide specificity mutants 
 





Mutant EF3 Mutations EF4 Mutations 
10 E87Q                                                  Q143R  
48 E84C               M124S              A128G  M144T K148Y  
54 E84D  R106C  D118N  M124F  E127L  A128H  M144I  K148Y  
56 E84G  L105V                                                     M144T K148R  




Figure 4.4  Stabilizing effect of Arg-106 and Asp-118.  In native calmodulin (PDB 1CDL) 
complexed with smMLCK peptide (magenta), Arg-106 located on the C-terminal half of 
EF3 (light blue) and Asp-118 on the C-terminal half of EF4 (dark blue) form a salt 





positions. A fourth mutation (D118N) by itself is a relatively conservative change, but 
coupled with the R106C mutation could have a significant role in altering specificity.  
Namely, without the additional stabilizing interaction of the Arg-106-Asp-118 salt bridge 
the EF3 and EF4 hands may be able to associate more freely and bind the scrambled 
peptide in a different orientation than the smMLCK peptide.  Finally, three positions 
(E127L, A128H, and K148Y) experienced drastic changes going from charged residues 
to hydrophobic residues or vice versa.  These mutations could provide adequate 
enough rearrangement of hydrophobic and charged residues within the EF hands to 
accompany the changes in distribution of charged and hydrophobic residues of the 
scrambled peptide.    Together, the rearrangement of charged and hydrophobic 
residues along with the possible additional flexibility afforded by the double R106C and 
D118N mutations may provide the right combination of changes for the switch to bind 
ICAM-1 in response to the scrambled peptide.   
4.4  Conclusion 
  To expand this technology further towards being commercially viable, it is 
important to demonstrate the design flexibility available in constructing a protein switch 
of this nature. The ability to engineer a protein switch to respond to a new effector 
molecule has been attempted many different times with varying degrees of success.17; 
85; 116; 117 Previously, this fusion protein had been engineered to demonstrate about a 
70-fold increase in ICAM-1 binding in the presence of smMLCK peptide compared to a 
scrambled version of smMLCK.  In this study, as a proof-of-concept, we flipped the 
specificity of the effector peptide for the switch protein from smMLCK to the scrambled 
peptide.  Five mutants isolated after four rounds of directed evolution and fluorescence-
activated cell sorting (FACS) showed a roughly 2-fold increase in ICAM-1 binding in the 
presence of scrambled peptide compared to smMLCK.  While this is a very modest 
switching activity, additional directed evolution could be used to further improve the 
activity of the switch by improving the affinity of the EF3 and EF4 hands for the 
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scrambled peptide.  Tighter binding of the scrambled peptide by the calmodulin domains 
would likely improve the switch function of the protein by providing a greater 
perturbation in the allosteric region of the I domain. 
104 
 
Chapter 5 :  Summary and Recommendations 
5.1  Summary 
 The ability of proteins to change their shape allows them to perform their unique 
functions.  Here, we have studied two proteins which undergo conformational 
rearrangements in response to external stimuli.  Hemagglutinin, a viral fusion protein 
found on the surface of influenza, refolds into an extended conformation at low pH.  The 
conformational refolding of hemagglutinin results in the fusion peptide becoming 
exposed and likely inserting into the target membrane leading to membrane fusion. 
Identification of mutations that stabilize or destabilize the neutral pH structure of 
hemagglutinin may lead to better understanding of the structure-function relationship of 
the protein.  Previous directed evolution work produced a series of mutants that refolded 
at a different pH than wild-type fowl-plague virus (FPV) HA. The mutants were analyzed 
to identify individual residues that were responsible for the altered conformational 
stability.  The results indicate that the HA1 head group is vitally important in controlling 
acid-induced refolding as four out of the six mutations that altered stability were found in 
the HA1 headgroup.  
 The entire ligand binding site for the lymphocyte function-associated antigen-1 
(LFA-1 integrin αLβ2) is contained solely within the inserted (I) domain of the α chain of 
the integrin.  Affinity for the I domain ligand, ICAM-1, which is overexpressed on 
inflamed endothelium is allosterically regulated.  Downward displacement of the C-
terminal α7 helix causes a disruption in the hydrophobic core of the I domain leading to 
rearrangement of residues in the metal ion-dependent adhesion site (MIDAS) resulting 
in higher affinity.  This allosteric rearrangement was exploited to create a chimeric 
fusion protein whose affinity for ICAM-1 was regulated by the presence of an 
exogenous peptide.  Directed evolution was used to improve the functional activity of 
this protein switch and to alter the specificity of the activating peptide 
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 Both proteins, hemagglutinin and the I domain-calmodulin fusion, represent the 
importance of conformational changes in controlling protein function.  The ability to 
manipulate these changes underscores the power of protein engineering and directed 
evolution and can lead to the development of complex biomolecules that can be used in 
a variety of applications from biosensing to molecular imaging to drug delivery. 
5.2   Engineering Protein Switches 
 The first aim of this dissertation was to engineer improved molecular switches via 
circular permutation.  Circular permutation has proven a successful approach for 
identifying non-obvious sites for domain insertion to more closely couple the functions of 
two disparate protein domains in order to effect greater switch activity.  Circular 
permutation was used to identify sites within the I domain amenable to domain insertion 
by sorting for permuted I domains that retained ICAM-1 binding.  A population of 
circularly permuted I domains was enriched 17-fold for ICAM-1 binders; however, upon 
sequence analysis of clones from this population it was apparent that the only site that 
was tolerant of new termini was the allosteric region of the I domain.  This information 
was used to then focus mutagenesis of a subsequent library on the allosteric region of 
protein.  By focusing the mutagenesis efforts in this region, along with alternating 
between positive and negative sorts, the likelihood of identifying mutations that would 
be beneficial to improved switch activity was increased.  Mutations identified through 
cell sorting were combined to determine a complementary set of amino acid changes 
that simultaneously improved the off-state of the switch (i.e., minimal ICAM-1 binding in 
the presence of the scrambled peptide) and retained or improved the on-state of the 
protein (i.e., retained or improved ICAM-1 affinity in the presence of smMLCK peptide).  
Mutant, M12, emerged for the directed evolution studies with a near twenty-fold 
increase in switch activity.  This mutant contained a total of three mutations: L289R, 
Y307S, and M337V.  The most significant being L289R, helping to stabilize the off-state 
of the switch.  This mutation results in a salt bridge between the β6-α7 loop and the α7 
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helix stabilizing the closed conformation of the I domain until a sufficient enough strain 
on the α7 helix, resulting from the binding of smMLCK peptide, breaks this interaction 
allowing the I domain to bind ICAM-1 with higher affinity. The other two mutations, 
Y307S and M337V, likely contribute to greater conformational flexibility (Y307S) and 
increased peptide affinity (M337V). 
 Demonstrating that both domains of an adhesive protein switch can be 
engineered expands the potential of this technology.  To that end, we demonstrated that 
it was possible to alter the specificity of the peptide to which the switch responds.  In the 
original and improved constructs, smMLCK peptide acted as the agonist peptide 
increasing the I domain affinity for ICAM when the peptide was present.  Conversely, 
when a scrambled version of the smMLCK peptide was present as a negative control, 
the I domain remained in a lower affinity state as the EF hands did not bind the peptide 
therefore not inducing the high affinity state.  As a proof of concept, directed evolution 
was used to change the protein switch‟s response to each of these peptides.  In 
essence, smMLCK peptide now served as a negative control while the scrambled 
peptide served as the agonist peptide inducing a higher affinity conformation of I 
domain.  Directed evolution was used to isolate a number of different mutants that 
responded specifically to scrambled peptide.   
5.3  Characterizing Protein Switches 
 The two proteins in this study required various degrees of characterization.  
Hemagglutinin, which undergoes an acid-induced conformational switch, had individual 
point mutants introduced to identify residues that were responsible for the altered pH 
stabilities.  Fifteen of the sixteen mutations found through a previous directed evolution 
experiment and characterized in this work had never before been found highlighting the 
power of directed evolution studies.  More importantly to this work, examination of these 
individual residues highlighted the importance of the HA1 headgroup in pH sensing and 
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conformational stability. Four mutations (I96M, G237R, W243S, and G365C) were 
found to destabilize the HA trimer with three of the four residues being located in the 
HA1 headgroup.  Additionally, W243S and G365C are highly conserved residues across 
all HA subtypes.  Two mutations (D247N and S429P) stabilizing the neutral pH structure 
were also identified.  Again, one of the mutations, D247N, was found at the interface 
between two HA1 headgroups and is believed to alleviate the native charge repulsion 
present between D247 and E414.  The majority of these pH-sensing residues are 
located in the HA1 headgroup signifying its importance in the conformational switching 
activity of hemagglutinin.  The majority of previously identified pH sensing residues have 
been located in the HA2 domain of hemagglutinin, implicating this subunit as the 
critically involved in pH sensing.  Our results indicate that it is very likely that the HA1 
headgroup controls pH sensing and thus triggers HA refolding since it needs to be 
displaced from its neutral location in order for HA2 to refold to its extended low pH 
conformation. 
5.3  Recommendations 
5.3.1  Characterization of altered specificity switches  
 While we have shown the ability to alter the peptide specificity of the EF3 and 
EF4 hands of our chimeric protein switch further engineering should be pursued to 
improve the activity of the switch.  While decreased affinity for ICAM-1 wasn‟t 
unexpected, likely due to low affinity binding of the calmodulin domains to scrambled 
peptide, it would need to be improved to fully exhibit the potential of engineering a 
chimeric, adhesive switch.  Further mutagenesis using a loop shuffling approach, similar 
to that used to engineer high affinity fibronectin type III (Fn3) binders to lysozyme,118 
would take advantage of the mutations already found to be beneficial while expanding 
the diversity to identify mutants with higher affinity for scrambled peptide thus improving 
the switch activity.  If loop shuffling failed to improve the altered peptide specificity 
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switches a true DNA shuffling approach, where the gene is randomly fragmented, could 
then be undertaken to improve the new generation of switches.  Following identification 
of an improved, scrambled peptide specific switch, site-directed mutagenesis could be 
used to try and gain further insight into the new binding mechanism.  Finally, binding 
kinetics using soluble proteins could be used for characterization consistent with 
previously developed switch mutants in our lab. 
5.3.2  Crystal structure of the protein switch  
 Structural determination of wild-type switch, switch M12 and possibly an altered 
peptide specificity switch could greatly benefit this work.  While it would be an arduous 
process and would require collaboration with another lab, structures of these switches in 
both the bound and unbound states would provide the final atomic details and complete 
our understanding of how these switches are functioning.  Specifically, a better 
understanding of how peptide binding gets allosterically translated to the MIDAS to alter 
ICAM-1 binding could be discovered.  Both x-ray crystallography and NMR would need 
to be used to resolve the actual structure in detail and to gain insight into the dynamics 
of the switch upon peptide binding. 
5.3.3  Expansion of Protein switch work 
Engineering an adhesive protein switch that has essentially two orthogonal states 
dependent upon the presence of peptide is a not only a significant achievement but also 
unique in the approach.  To date, the vast majority of protein switches have been 
developed to respond to small ligands (e.g., sugars, ions, light, etc.)17; 18; 19; 97; 119  
making their use in a therapeutic application in the near future unlikely.  Given that the I 
domain of LFA-1 is already critical to the inflammatory cascade, demonstrating the 
ability to engineer clinically relevant domains as fusions to the I domain to effect control 
of ICAM-1 binding would make this approach very attractive for a number of different 
applications.  Previously, the αL I domain has been conjugated to the surface of 
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nanoparticles for targeted delivery of drug and gene therapies to cells over expressing 
ICAM-1 both in vitro and in vivo.25; 26; 27  These molecules use previously engineered 
high affinity I domain28 to selectively target ICAM-1 making these nanoparticles highly 
efficient at targeting tumors where drug delivery by the permeability and retention (EPR) 
effect is less efficient.  Designing a protein switch where I domain affinity is regulated by 
the presence of exogenous peptide would provide an additional layer of specificity in 
targeted imaging and delivery systems.  Further engineering of peptide specificity would 
enhance the targeting capabilities.     
  
5.6 Conclusions 
 This dissertation undertook the task of engineering and characterizing two 
distinct proteins both of which had distinct structural rearrangements, or switching 
actions, which contributed to their function.  Understanding and manipulating protein 
switches is a worthwhile endeavor for several reasons.  Manipulation of protein 
conformational changes can lead to a greater understanding of the structure-function 
relationship of a protein and the identification of key structural features can provide a 
good starting point for future protein engineering work.  Also, the ability to combine two 
distinct proteins and couple their functions holds tremendous potential for the design of 
future biomaterials.  The number of strategies or applications where the coupling of two or 
more proteins could be exploited for more precise control of an enzymatic reaction or protein 
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Appendix 1.  Site directed mutagenesis of HA primers 
 
Table A1. 1  Primers for sited directed mutagenesis of FPV HA 
Primer Sequence 
D93S 
5‟ – ATGCGACCAATTTCTAGAATTTTCAGCTAGTCTAATAATCGAGAGACGAG – 
3‟  
D93S_antisense 
5‟ -  CTCGTCTCTCGATTATTAGACTAGCTGAAAATTCTAGAAATTGGTCGCAT – 
3‟ 
I96M 5‟ – TCAGCTGATCTAATAATGGAGAGACGAGAAGGA – 3‟  
I96M_anti 5‟ – TCCTTCTCGTCTCTCCATTATTAGATCAGCTGA – 3‟ 
G142D 5‟ – GGAATAAGGACCAACGACACAACTAGTGCATGT – 3‟ 
G142D_anti 5‟ – ACATGCACTAGTTGTGTCGTTGGTCCTTATTCC – 3‟ 
FPV HA Y155F 5‟ – GGGTCTTCATTCTTTGCAGAAATGGAGTGG – 3‟ 
FPV HA Y155F_anti 5‟ – CCACTCCATTTCTGCAAAGAATGAAGACCC – 3‟ 
D166G 5‟ – CTGTCAAATACAGGCAATGCTTCTTTCCCA – 3‟ 
D166G_anti 5‟ – TGGGAAAGAAGCATTGCCTGTATTTGACAG – 3‟ 
FPV HA A168V 5‟ – GACAATACAGACAATGTTTCTTTCCCACAA – 3‟ 
FPV HA A168V_anti 5‟ – TTGTGGGAAAGAAACATTGTCTGTATTGTC – 3‟ 
V188G 5‟ – GAATCAGCTCTGATAGGATGGGGAATCCACCAT – 3‟ 
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Table A1.1  Continued  
Primer Sequence 
V188G_anti 5‟ – ATGGTGGATTCCCCATCCTATCAGAGCTGATTC – 3‟ 
Y218H 5‟ – GGGAGTTCCAAACATCATCAATCTTTTGTG – 3‟ 
Y218H_anti 5‟ – CACAAAAGATTGATGATGTTTGGAACTCCC – 3‟ 
D240Y 5‟ – GCCAGAGCGGACGGATTTATTTTCATTGGTTGATCT – 3‟ 
D240Y_antisense 5‟ – AGATCAACCAATGAAAATAAATCCGTCCGCTCTGGC – 3‟ 
D247N 
5‟ – GATTGATTTTCATTGGTTGATCTTGAATCCCAATGATACAGTTACTTTTAG – 
3‟ 
D247N_anti 
5‟ – CTAAAAGTAACTGTATCATTGGGATTCAAGATCAACCAATGAAAATCAATC – 
3‟ 
G237R 5‟ – AATGGCCAGTCCCGACGGATTGATTTTCAT – 3‟ 
G237R_anti 5‟ – ATGAAAATCAATCCGTCGGGACTGGCCATT – 3‟ 
W243S forward 5‟ – CGGATTGATTTTCATTCGTTGATCTTGGATCCC – 3‟ 
W243S reverse 5‟ – GGGATCCAAGATCAACGAATGAAAATCAATCCG – 3‟ 
G365C 5‟ – GAAGAAGACTTGTGGTACTGTTTCAGGCATCAGAATG – 3‟ 
G365C_antisense 5‟ – CATTCTGATGCCTGAAACAGTACCACAAGTCTTCTTC – 3‟ 
L407A 5‟ – ACCAACCAGCAATTTGAGGCAATAGATAATGAA – 3‟ 
L407A_anti 5‟ – TTCATTATCTATTGCCTCAAATTGCTGGTTGGT – 3‟ 
123 
 
Table A1.1  Continued  
Primer Sequenc 
S429P 5‟ – AACTGGACCAAAGACCCCATCACAGAAGTATGG – 3‟ 
S429P_anti 5‟ – CCATACTTCTGTGATGGGGTCTTTGGTCCAGTT – 3‟ 
E462Q 5‟ – TCAGAGATGAACAGGCTGTATCAGCGAGTGAGG – 3‟ 
E462Q_antisense 5‟ – CCTCACTCGCTGATACAGCCTGTTCATCTCTGA – 3‟ 
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Appendix 2.  pH transition curves for pH 4.8 selected mutants 
 
 




Appendix 3.  pH transition curves for pH 5.6 selected mutants 
 
 




Appendix 4.  pH transition curves for pH 6.0 selected mutants 
 
 





Appendix 5.  Yeast surface display construct 
 
Figure A5. 1  Yeast surface display construct showing a protein switch.  Proteins are 
displayed as C-terminal fusions to Aga2p with two epitope tags (HA and c-myc) on 
either side of the protein of interest.  Commercial antibodies against either epitope can 
be used to assay surface expression level.  For ICAM binding, an ICAM-Fc fusion (R&D 
Systems) was precomplexed with an anti-Fc AlexaFluor 647 antibody (Jackson 
ImmunoResearch) and the precomplexed ICAM/Anti-Fc AF647 was used to assess I 
domain or switch affinity.
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Appendix 6.  Circular permutation primers  
 
Table A6. 3  Primers for addition of AfeI restriction site 
Primer Name Sequence 
AfeI - rc A4 for 5’ -  GCTAGCAGCGCTTGTATCAAGGGCAACGTAG – 3’ 
AfeI – rc A4 rev 5’ – GGATCCAGCGCTGCCCTCAATGACATAGATCT – 3’ 
Note:  Primers for insertion of AfeI restriction site for blunt-end ligation into pCT302 to 
create pCT-JVP 
 
Table A6. 4  Primers for the addition of GGGSG linker for circular permutation 
Primer Name Sequence 
N-Id 6 Linker Cp 5’ – GGATCCGGTGGTTGTATCAAGGGCAACGTA – 3’  
C-Id 5&6 Linker Cp 5’ – GGATCCACCACCGCCCTCAATGACATA – 3’  
Note:  Primers used to add short Gly-Ser linker when circularized with BamHI 













Figure A7. 1  Circular permutation of I domain.  Lane 1:  1 kb+ DNA ladder, lane 2:  
linearized I domain, lane3: circularly ligated I domain, lane 4:  ExoIII digested ligation, 




1 2 3 4 5 6 7 
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Appendix 8.  pCT Switch plasmid 
 
           
Figure A8. 1  pCT302 showing the switch gene located between NheI and BamHI 
restriction sites. 
 
5’ -  -  3’ 
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Appendix 9.  Two color flow cytometry plots of engineered switches. 
 
Figure A9. 1  Two color flow cytometry plots of engineered switches.  In all plots, 
populations in blue represent switches that were incubated with scrambled peptide and 
populations shown in red represent switches incubated with smMLCK peptide.  The 
vertical axis represents the amount of surface expressed protein and the horizontal axis 
represents the amount of bound ICAM-1.  Each dot represents an individual cell.  Cells 
located above the horizontal gate are considered to contain full length protein on the 


























Appendix 10.  Representative sensorgrams for I domain/EF hands switches. 
 
 
Figure A10. 1  Representative sensorgram of a first generation I domain/EF hands 
switch.  Sensorgrams were generated using a Biacore 3000 where ICAM-1-Fc was 
immobilized on a CM5 sensor chip using amine coupling.  First generation switches 
(SW1 and SW9) were incubated for at least 1 hour with either smMLCK peptide or 
scrambled peptide and then injected.  Switches were allowed to associate for four 
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